1
|
Tanigaki T, Ogawa T, Nomura S, Ito K, Kurata Y, Matsukida A, Ishihara M, Yoshino A, Kawana A, Kimizuka Y. Severe Atelectasis due to Aspirated Valproic Acid Tablet. Case Rep Pulmonol 2024; 2024:6650141. [PMID: 38529055 PMCID: PMC10963110 DOI: 10.1155/2024/6650141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 02/20/2024] [Accepted: 03/09/2024] [Indexed: 03/27/2024] Open
Abstract
A 60-year-old man treated with valproic acid (VPA) for epilepsy developed atelectasis and respiratory failure after an accidentally aspirated VPA tablet-induced mucus hypersecretion. Following bronchoscopic removal of the aspirated tablet, his respiratory status improved and massive sputum production did not recur. We hypothesized that the aspirated VPA tablet increased the expression of mucin-related genes, thereby increasing mucus production. Our in vitro experiments using a human respiratory epithelial cell line revealed that VPA directly upregulates the airway mucin-related genes. We believe that this is the first case report of aspirated VPA-induced severe atelectasis and respiratory failure, which were successfully treated with the bronchoscopic removal of the VPA tablet.
Collapse
Affiliation(s)
- Tomomi Tanigaki
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Takunori Ogawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Sakika Nomura
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Koki Ito
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Yuhei Kurata
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Akira Matsukida
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Morio Ishihara
- Division of Psychiatry, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Aihide Yoshino
- Division of Psychiatry, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| |
Collapse
|
2
|
Nishimura M, Ogawa T, Tanigaki T, Sumi K, Enjoji Y, Suyama Y, Kawana A, Kimizuka Y. Massive pleural effusion in porous diaphragm syndrome due to lymphatic leakage after pelvic surgery. Respirol Case Rep 2024; 12:e01338. [PMID: 38528947 PMCID: PMC10963128 DOI: 10.1002/rcr2.1338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2024] [Accepted: 03/19/2024] [Indexed: 03/27/2024] Open
Abstract
We present the case of a patient who developed a massive right pleural effusion after pelvic surgery, not thoracic surgery. Lymphatic leakage into the abdominal cavity after pelvic surgery can cause massive pleural effusion when complicated with porous diaphragm syndrome.
Collapse
Affiliation(s)
- Masashi Nishimura
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Takunori Ogawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Tomomi Tanigaki
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Koji Sumi
- Department of RadiologyNational Defense Medical CollegeSaitamaJapan
| | - Yasuhiro Enjoji
- Department of RadiologyNational Defense Medical CollegeSaitamaJapan
| | - Yohsuke Suyama
- Department of RadiologyNational Defense Medical CollegeSaitamaJapan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| |
Collapse
|
3
|
Nishimura M, Kimizuka Y, Ogawa T, Tsuchiya M, Kato Y, Matsukida A, Igarashi S, Ito K, Serizawa Y, Tanigaki T, Fujikura Y, Katsurada Y, Ogata S, Kawana A. IgG4-related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with non-small cell lung cancer: A case report. Thorac Cancer 2024; 15:104-107. [PMID: 38098256 PMCID: PMC10761607 DOI: 10.1111/1759-7714.15155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 01/04/2024] Open
Abstract
IgG4-related diseases are adverse events that occur after receiving treatment with immune checkpoint inhibitors (ICI). This study reports the first case of IgG4-related retroperitoneal fibrosis after the administration of chemotherapy with nivolumab and ipilimumab (NI therapy). An 80-year-old man developed lower abdominal pain eight months after NI therapy was initiated. Although the primary lesion maintained its reduced size on computed tomography, there was an increase in the soft tissue shadows intensity around the abdominal aorta, bladder, and seminal vesicles, suggesting retroperitoneal fibrosis. Blood tests showed elevated IgG4 levels. Computed tomography-guided biopsy of the retroperitoneum showed B cell-dominant lymphocyte infiltration consistent with IgG4-related retroperitoneal fibrosis and characteristic CD8-positive lymphocyte infiltration, suggestive of the involvement of cytotoxic T cells. Based on the clinical, imaging, and pathological findings, the patient was diagnosed with IgG4-related retroperitoneal fibrosis due to ICI. Immunotherapy discontinuation alone did not result in improvement; therefore, steroid therapy was initiated. In clinical practice, IgG4-related retroperitoneal fibrosis can occur as an immune-related adverse event when administering anti-PD-1 and anti-CTLA-4 antibodies for cancer immunotherapy. Early steroid therapy could be effective in controlling this immune-related adverse event.
Collapse
Affiliation(s)
- Masashi Nishimura
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Takunori Ogawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Motohiro Tsuchiya
- Department of Pathology and Laboratory MedicineNational Defense Medical CollegeSaitamaJapan
| | - Yoshiki Kato
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Akira Matsukida
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Shunya Igarashi
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Koki Ito
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Yusuke Serizawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Tomomi Tanigaki
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Yuji Fujikura
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | - Yuka Katsurada
- Department of Pathology and Laboratory MedicineNational Defense Medical CollegeSaitamaJapan
| | - Sho Ogata
- Department of Pathology and Laboratory MedicineNational Defense Medical CollegeSaitamaJapan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| |
Collapse
|
4
|
Terai H, Ishii M, Takemura R, Namkoong H, Shimamoto K, Masaki K, Tanosaki T, Chubachi S, Matsuyama E, Hayashi R, Shimada T, Shigematsu L, Ito F, Kaji M, Takaoka H, Kurihara M, Nakagawara K, Tomiyasu S, Sasahara K, Saito A, Otake S, Azekawa S, Okada M, Fukushima T, Morita A, Tanaka H, Sunata K, Asaoka M, Nishie M, Shinozaki T, Ebisudani T, Akiyama Y, Mitsuishi A, Nakayama S, Ogawa T, Sakurai K, Irie M, Yagi K, Ohgino K, Miyata J, Kabata H, Ikemura S, Kamata H, Yasuda H, Kawada I, Kimura R, Kondo M, Iwasaki T, Ishida N, Hiruma G, Miyazaki N, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H, Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Haraguchi M, Kagyo J, Shiomi T, Lee H, Sugihara K, Omori N, Sayama K, Otsuka K, Miyao N, Odani T, Watase M, Mochimaru T, Satomi R, Oyamada Y, Masuzawa K, Asakura T, Nakayama S, Suzuki Y, Baba R, Okamori S, Arai D, Nakachi I, Kuwahara N, Fujiwara A, Oakada T, Ishiguro T, Isosno T, Makino Y, Mashimo S, Kaido T, Minematsu N, Ueda S, Minami K, Hagiwara R, Manabe T, Fukui T, Funatsu Y, Koh H, Yoshiyama T, Kokuto H, Kusumoto T, Oashi A, Miyawaki M, Saito F, Tani T, Ishioka K, Takahashi S, Nakamura M, Harada N, Sasano H, Goto A, Kusaka Y, Ohba T, Nakano Y, Nishio K, Nakajima Y, Suzuki S, Yoshida S, Tateno H, Kodama N, Shunsuke M, Sakamoto S, Okamoto M, Nagasaki Y, Umeda A, Miyagawa K, Shimada H, Hagimura K, Nagashima K, Sato T, Sato Y, Hasegawa N, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K, Amagai M, Goto R, Ibuka Y, Kitagawa Y, Kanai T, Fukunaga K. Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study. Respir Investig 2023; 61:802-814. [PMID: 37783167 DOI: 10.1016/j.resinv.2023.08.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 07/15/2023] [Accepted: 08/16/2023] [Indexed: 10/04/2023]
Abstract
BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly since 2019, and the number of reports regarding long COVID has increased. Although the distribution of long COVID depends on patient characteristics, epidemiological data on Japanese patients are limited. Hence, this study aimed to investigate the distribution of long COVID in Japanese patients. This study is the first nationwide Japanese prospective cohort study on long COVID. METHODS This multicenter, prospective cohort study enrolled hospitalized COVID-19 patients aged ≥18 years at 26 Japanese medical institutions. In total, 1200 patients were enrolled. Clinical information and patient-reported outcomes were collected from medical records, paper questionnaires, and smartphone applications. RESULTS We collected data from 1066 cases with both medical records and patient-reported outcomes. The proportion of patients with at least one symptom decreased chronologically from 93.9% (947/1009) during hospitalization to 46.3% (433/935), 40.5% (350/865), and 33.0% (239/724) at 3, 6, and 12 months, respectively. Patients with at least one long COVID symptom showed lower quality of life and scored higher on assessments for depression, anxiety, and fear of COVID-19. Female sex, middle age (41-64 years), oxygen requirement, and critical condition during hospitalization were risk factors for long COVID. CONCLUSIONS This study elucidated the symptom distribution and risks of long COVID in the Japanese population. This study provides reference data for future studies of long COVID in Japan.
Collapse
Affiliation(s)
- Hideki Terai
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Keio Cancer Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Furocho, Chikusa Ward, Nagoya, Aichi, 466-8550, Japan
| | - Ryo Takemura
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Ho Namkoong
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kyoko Shimamoto
- Keio Global Research Institute, Keio University, 2-15-45 Mita, Minato-ku, Tokyo, 108-8345, Japan
| | - Katsunori Masaki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Takae Tanosaki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Shotaro Chubachi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Emiko Matsuyama
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Reina Hayashi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Takashi Shimada
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Lisa Shigematsu
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Fumimaro Ito
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Masanori Kaji
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Hatsuyo Takaoka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Momoko Kurihara
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kensuke Nakagawara
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Saki Tomiyasu
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kotaro Sasahara
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Ayaka Saito
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Shiro Otake
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Shuhei Azekawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Masahiko Okada
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Takahiro Fukushima
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Atsuho Morita
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Hiromu Tanaka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Keeya Sunata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Masato Asaoka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Miyuki Nishie
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Taro Shinozaki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Toshiki Ebisudani
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Yuto Akiyama
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Akifumi Mitsuishi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Shingo Nakayama
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kaori Sakurai
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Misato Irie
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kazuma Yagi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Keiko Ohgino
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Jun Miyata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Hiroki Kabata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Shinnosuke Ikemura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Hiroyuki Yasuda
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Ichiro Kawada
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Ryusei Kimura
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Masahiro Kondo
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Toshiki Iwasaki
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Noriyuki Ishida
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Gaku Hiruma
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Naoki Miyazaki
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Yoshiki Ishibashi
- Department of Preventive Medicine and Public Health, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Sei Harada
- Department of Preventive Medicine and Public Health, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Takanori Fujita
- Department of Health Policy and Management, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Daisuke Ito
- Department of Physiology/Memory Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Shogyoku Bun
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Hajime Tabuchi
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Sho Kanzaki
- Department of Otolaryngology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Eisuke Shimizu
- Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Keitaro Fukuda
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Jun Yamagami
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Keigo Kobayashi
- Department of Internal Medicine, Sano Kosei General Hospital, 1728 Horigomecho, Sano, Tochigi, 327-8511, Japan
| | - Toshiyuki Hirano
- Department of Internal Medicine, Sano Kosei General Hospital, 1728 Horigomecho, Sano, Tochigi, 327-8511, Japan
| | - Takashi Inoue
- Department of Internal Medicine, Sano Kosei General Hospital, 1728 Horigomecho, Sano, Tochigi, 327-8511, Japan
| | - Mizuha Haraguchi
- Department of Internal Medicine, Keiyu Hospital, Kanagawa, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-0012, Japan
| | - Junko Kagyo
- Department of Internal Medicine, Keiyu Hospital, Kanagawa, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-0012, Japan
| | - Tetsuya Shiomi
- Department of Internal Medicine, Keiyu Hospital, Kanagawa, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa, 220-0012, Japan
| | - Ho Lee
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Division of Pulmonary Medicine, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| | - Kai Sugihara
- Division of Pulmonary Medicine, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| | - Nao Omori
- Division of Pulmonary Medicine, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| | - Koichi Sayama
- Division of Pulmonary Medicine, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa, 210-0013, Japan
| | - Kengo Otsuka
- Department of Internal Medicine, Nihon Koukan Hospital, 1-2-1 Kokandori, Kawasaki-ku, Kawasaki, Kanagawa, 210-0852, Japan
| | - Naoki Miyao
- Department of Internal Medicine, Nihon Koukan Hospital, 1-2-1 Kokandori, Kawasaki-ku, Kawasaki, Kanagawa, 210-0852, Japan
| | - Toshio Odani
- Department of Rheumatology, National Hospital Organization Hokkaido Medical Center, 7-1-1 Yamanote 5 Jo, Nishi-ku, Sapporo, Hokkaido, 063-0005, Japan
| | - Mayuko Watase
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Department of Respiratory Medicine, National Hospital Organisation Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan
| | - Takao Mochimaru
- Department of Respiratory Medicine, National Hospital Organisation Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan
| | - Ryosuke Satomi
- Department of Respiratory Medicine, National Hospital Organisation Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan
| | - Yoshitaka Oyamada
- Department of Respiratory Medicine, National Hospital Organisation Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan
| | - Keita Masuzawa
- Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8642, Japan
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8642, Japan
| | - Sohei Nakayama
- Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8642, Japan
| | - Yusuke Suzuki
- Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8642, Japan
| | - Rie Baba
- Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, 911-1 Takebayashimachi, Utsunomiya, Tochigi, 321-0974, Japan
| | - Satoshi Okamori
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, 911-1 Takebayashimachi, Utsunomiya, Tochigi, 321-0974, Japan
| | - Daisuke Arai
- Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, 911-1 Takebayashimachi, Utsunomiya, Tochigi, 321-0974, Japan
| | - Ichiro Nakachi
- Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, 911-1 Takebayashimachi, Utsunomiya, Tochigi, 321-0974, Japan
| | - Naota Kuwahara
- Department of Medicine, Division of Allergology and Respiratory Medicine, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo, 135-8577, Japan
| | - Akiko Fujiwara
- Department of Medicine, Division of Allergology and Respiratory Medicine, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo, 135-8577, Japan
| | - Takenori Oakada
- Department of Medicine, Division of Allergology and Respiratory Medicine, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo, 135-8577, Japan
| | - Takashi Ishiguro
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, 1696 Itai, Kumagaya, Saitama, 360-0197, Japan
| | - Taisuke Isosno
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, 1696 Itai, Kumagaya, Saitama, 360-0197, Japan
| | - Yasushi Makino
- Department of Respiratory Medicine, Toyohashi Municipal Hospital, 50 Hachikennishi, Aotakecho, Toyohashi, Aichi, 441-8570, Japan
| | - Shuko Mashimo
- Department of Respiratory Medicine, Toyohashi Municipal Hospital, 50 Hachikennishi, Aotakecho, Toyohashi, Aichi, 441-8570, Japan
| | - Tatsuya Kaido
- Department of Respiratory Medicine, Toyohashi Municipal Hospital, 50 Hachikennishi, Aotakecho, Toyohashi, Aichi, 441-8570, Japan
| | - Naoto Minematsu
- Department of Internal Medicine, Hino Municipal Hospital, 4-3-1, Tamadaira, Hino-city, Tokyo, 191-0062, Japan
| | - Soichiro Ueda
- Department of Internal Medicine, Saitama Medical Center, 1981 Kamoda, Kawagoeshi, Saitama, 350-8550, Japan
| | - Kazuhiro Minami
- Department of Internal Medicine, Saitama Medical Center, 1981 Kamoda, Kawagoeshi, Saitama, 350-8550, Japan
| | - Rie Hagiwara
- Department of Internal Medicine, Saitama Medical Center, 1981 Kamoda, Kawagoeshi, Saitama, 350-8550, Japan
| | - Tadashi Manabe
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, 4-2-22 Nishikicho, Tachikawa, Tokyo, 190-8531, Japan
| | - Takahiro Fukui
- Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, 4-2-22 Nishikicho, Tachikawa, Tokyo, 190-8531, Japan
| | - Yohei Funatsu
- Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, 4-2-22 Nishikicho, Tachikawa, Tokyo, 190-8531, Japan
| | - Hidefumi Koh
- Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, 4-2-22 Nishikicho, Tachikawa, Tokyo, 190-8531, Japan
| | - Takashi Yoshiyama
- Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo, 204-8522, Japan
| | - Hiroyuki Kokuto
- Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo, 204-8522, Japan
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Department of Pulmonary Medicine, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo, 110-8645, Japan
| | - Ayano Oashi
- Department of Pulmonary Medicine, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo, 110-8645, Japan
| | - Masayoshi Miyawaki
- Department of Pulmonary Medicine, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo, 110-8645, Japan
| | - Fumitake Saito
- Department of Pulmonary Medicine, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo, 110-8645, Japan
| | - Tetsuo Tani
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo, 108-0073, Japan
| | - Kota Ishioka
- Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo, 108-0073, Japan
| | - Saeko Takahashi
- Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo, 108-0073, Japan
| | - Morio Nakamura
- Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo, 108-0073, Japan
| | - Norihiro Harada
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Hitoshi Sasano
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Ai Goto
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Yu Kusaka
- Department of Respiratory Medicine, Ome Municipal General Hospital, 4-16-5, Higashiome, Ome, Tokyo, 198-0042, Japan
| | - Takehiko Ohba
- Department of Respiratory Medicine, Ome Municipal General Hospital, 4-16-5, Higashiome, Ome, Tokyo, 198-0042, Japan
| | - Yasushi Nakano
- Department of Pulmonary Medicine, Kawasaki Municipal Ida Hospital, 2-27-1 Ida, Nakahara-ku, Kawasaki-shi, Kanagawa, 211-0035, Japan
| | - Kazumi Nishio
- Department of Pulmonary Medicine, Kawasaki Municipal Ida Hospital, 2-27-1 Ida, Nakahara-ku, Kawasaki-shi, Kanagawa, 211-0035, Japan
| | - Yukiko Nakajima
- Department of Infectious Disease, Kawasaki Municipal Ida Hospital, 2-27-1 Ida, Nakahara-ku, Kawasaki-shi, Kanagawa, 211-0035, Japan
| | - Shoji Suzuki
- Department of Pulmonary Medicine, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama, 336-8522, Japan
| | - Shuichi Yoshida
- Department of Pulmonary Medicine, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama, 336-8522, Japan
| | - Hiroki Tateno
- Department of Pulmonary Medicine, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama, 336-8522, Japan
| | - Nobuhiro Kodama
- Department of General Internal Medicine, Fukuoka Tokushukai Hospital, 4-5 Sugukita, Kasuga, Fukuoka, 816-0864, Japan
| | - Maeda Shunsuke
- Department of General Internal Medicine, Fukuoka Tokushukai Hospital, 4-5 Sugukita, Kasuga, Fukuoka, 816-0864, Japan
| | - Satoshi Sakamoto
- Department of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan
| | - Masaki Okamoto
- Department of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan; Department of Respirology, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan
| | - Yoji Nagasaki
- Department of Infectious Disease and Clinical Research Center, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan
| | - Akira Umeda
- Department of Respiratory Medicine, International University of Health and Welfare Shioya Hospital, 2600-1 Kitakanemaru, Otawara, Tochigi, 324-8501, Japan
| | - Kazuya Miyagawa
- Department of Pharmacology, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Otawara, Tochigi, 324-8501, Japan
| | - Hisato Shimada
- Department of Pharmacology, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Otawara, Tochigi, 324-8501, Japan
| | - Kazuto Hagimura
- Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kengo Nagashima
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Toshiro Sato
- Department of Organoid Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Yasunori Sato
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Department of Preventive Medicine and Public Health, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Naoki Hasegawa
- Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Toru Takebayashi
- Department of Preventive Medicine and Public Health, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Jin Nakahara
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Masaru Mimura
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kaoru Ogawa
- Department of Otolaryngology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Shigeto Shimmura
- Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kazuno Negishi
- Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kazuo Tsubota
- Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Masayuki Amagai
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Rei Goto
- Graduate School of Business Administration, Keio University, 4-1-1 Hiyoshi Kohoku-ku, Yokohama, Kanagawa, 223-8526, Japan
| | - Yoko Ibuka
- Faculty of Economics, Keio University, 2-15-45 Mita, Minato-ku, Tokyo, 108-8345, Japan
| | - Yuko Kitagawa
- Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Takanori Kanai
- Division of Gastroenterology and Hepatology Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
| |
Collapse
|
5
|
Tokoro S, Ogawa T, Hayashi S, Igawa K. High-resolution mass spectrometry imaging reveals skin lipid changes and the cholesterol sulphate cycle during keratinization. J Eur Acad Dermatol Venereol 2023. [PMID: 37909310 DOI: 10.1111/jdv.19621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Accepted: 10/27/2023] [Indexed: 11/03/2023]
Affiliation(s)
- S Tokoro
- Department of Dermatology, Dokkyo Medical University, Tochigi, Japan
| | - T Ogawa
- Research Center for Advanced Medical Sciences, Dokkyo Medical University, Tochigi, Japan
| | - S Hayashi
- Department of Dermatology, Dokkyo Medical University, Tochigi, Japan
| | - K Igawa
- Department of Dermatology, Dokkyo Medical University, Tochigi, Japan
| |
Collapse
|
6
|
Ogawa T, Arakawa M, Suzuki T, Yasuno N, Tanaka M, Hidaka S. Relationship between office blood pressure and actual antihypertensive drug use in patients with hypertension following the promulgation of the guidelines for hypertension (JSH2019). Pharmazie 2023; 78:212-215. [PMID: 38037214 DOI: 10.1691/ph.2023.3587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/02/2023]
Abstract
To achieve appropriate blood pressure control in the treatment of hypertension in Japan, this study examined the relationship between office blood pressure and actual antihypertensive drug use in general hospitals following the promulgation of the guidelines for hypertension (JSH2019). This study focused on blood pressure levels and drug use in outpatients on antihypertensive treatment from June to July 2020. The subjects were 2,537 patients classified into four groups based on their medical history, patients with: hypertension only; hypertension and cardiovascular disease; hypertension and dyslipidaemia; and hypertension and diabetes mellitus. The results showed a significant difference in systolic blood pressure (SBP) between patients with hypertension only and those with hypertension and cardiovascular disease (138.3±17.9 mmHg vs 135.6±19.9 mmHg, p<0.05). Regarding actual drug use, it was found that diuretics were prescribed more frequently in patients with hypertension and cardiovascular disease than in those with hypertension alone (15.5% vs 37.9%, p<0.05), even though the number of drugs for hypertension did not differ significantly. In addition, the dose of diuretics was greater only in patients with cardiovascular disease. These results show the actual drug use and blood pressure for each comorbidity. Furthermore, they suggest that the results of antihypertensive treatment may differ by changing the combination and dosage of antihypertensive drugs without changing the number of antihypertensive drugs used. The study also shows the problem of using less diuretics depending on the risk the patient has, and solving the problem may lead to achieving further antihypertensive goals.
Collapse
Affiliation(s)
- T Ogawa
- Department of Pharmaceutical Regulatory Science, School of Pharmacy, Nihon University, Funabashi City, Chiba, Japan
| | - M Arakawa
- Department of Pharmaceutical Regulatory Science, School of Pharmacy, Nihon University, Funabashi City, Chiba, Japan
| | - T Suzuki
- Department of Pharmacy, KAN-ETSU Hospital, Tsurugashima-city, Saitama, Japan
| | - N Yasuno
- Department of Pharmacy, Teikyo University School of Medicine University Hospital, Teikyo University, Tokyo, Japan
| | - M Tanaka
- Department of Internal Medicine, KAN-ETSU Hospital, Tsurugashima-city, Saitama, Japan
| | - S Hidaka
- Department of Pharmaceutical Regulatory Science, School of Pharmacy, Nihon University, Funabashi City, Chiba, Japan
| |
Collapse
|
7
|
Maki Y, Edo N, Mizuguchi M, Ikeda M, Kitano M, Kitagami E, Osa M, Yamamoto S, Ogawa T, Nakamura T, Kawana A, Kimizuka Y. Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen®) vaccination on antibody titers; a japanese cross-sectional study. Vaccine 2023; 41:5974-5978. [PMID: 37620202 DOI: 10.1016/j.vaccine.2023.08.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Revised: 07/26/2023] [Accepted: 08/14/2023] [Indexed: 08/26/2023]
Abstract
BACKGROUND The effect of the timing of additional doses and the long-term persistence of lyophilized inactivated tissue culture hepatitis A (HA) vaccine (Aimmugen®) on antibodies is unknown. METHODS A single-center, cross-sectional, observational study was conducted in collaboration with the Japan Air Self-Defense Force, whose personnel were immunized with Aimmugen® when deployed to endemic areas. Patients who consented to this study after a medical examination with blood sampling between June 2022 and February 2023 were included; HA-IgG level in the residual serum was measured using the chemiluminescent immunoassay method. The exact vaccination history was investigated based on immunization records maintained by the Ministry of Defense, and a questionnaire was used to collect confounding factors. RESULTS Of the 181 participants observed, 49 were in the unvaccinated group, and 132 were in the vaccinated group. Out of the vaccinated group, 6.8 % received either one or two doses, 40.9 % received three doses, and 52.3 % received more than four doses. IgG antibody titers (S/CO value) in each group (0, 1 or 2, 3, and over 4) increased in a frequency-dependent manner, with those vaccinated over four times showing significantly higher IgG antibody titers than all other groups (0.19 ± 0.10 vs 3.66 ± 3.00 vs 7.63 ± 3.57 vs 10.57 ± 1.86, respectively). When the number of months elapsed from the last vaccination to the date of blood collection in each group was plotted against IgG antibody titer, the slope of the regression line flattened out from a decreasing trend in the order 1 or 2, 3, over 4. CONCLUSIONS Three doses of Aimmugen® are efficacious, but four or more doses induce more robust and sustained antibody production. Additionally, four or more doses may be effective when there is a need to ensure long-term immunity or risk of prolonged exposure.
Collapse
Affiliation(s)
- Yohei Maki
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Naoki Edo
- Division of Behavioral Science, National Defense Medical College Research Institute, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Makoto Mizuguchi
- Department of Healthcare, Japan Self-Defense Force Iruma Hospital, 2-1-4 Koyodai, Iruma, Saitama 358-0001, Japan
| | - Mikihito Ikeda
- Department of Dental, Japan Self-Defense Force Iruma Hospital, 2-1-4 Koyodai, Iruma, Saitama 358-0001, Japan
| | - Masato Kitano
- Division of Behavioral Science, National Defense Medical College Research Institute, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Etsuko Kitagami
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Morichika Osa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Shotaro Yamamoto
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Takunori Ogawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Takahiro Nakamura
- Department of Mathematics, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
| |
Collapse
|
8
|
Abe K, Akhlaq N, Akutsu R, Ali A, Alonso Monsalve S, Alt C, Andreopoulos C, Antonova M, Aoki S, Arihara T, Asada Y, Ashida Y, Atkin ET, Barbi M, Barker GJ, Barr G, Barrow D, Batkiewicz-Kwasniak M, Bench F, Berardi V, Berns L, Bhadra S, Blanchet A, Blondel A, Bolognesi S, Bonus T, Bordoni S, Boyd SB, Bravar A, Bronner C, Bron S, Bubak A, Buizza Avanzini M, Caballero JA, Calabria NF, Cao S, Carabadjac D, Carter AJ, Cartwright SL, Catanesi MG, Cervera A, Chakrani J, Cherdack D, Chong PS, Christodoulou G, Chvirova A, Cicerchia M, Coleman J, Collazuol G, Cook L, Cudd A, Dalmazzone C, Daret T, Davydov YI, De Roeck A, De Rosa G, Dealtry T, Delogu CC, Densham C, Dergacheva A, Di Lodovico F, Dolan S, Douqa D, Doyle TA, Drapier O, Dumarchez J, Dunne P, Dygnarowicz K, Eguchi A, Emery-Schrenk S, Erofeev G, Ershova A, Eurin G, Fedorova D, Fedotov S, Feltre M, Finch AJ, Fiorentini Aguirre GA, Fiorillo G, Fitton MD, Franco Patiño JM, Friend M, Fujii Y, Fukuda Y, Fusshoeller K, Giannessi L, Giganti C, Glagolev V, Gonin M, González Rosa J, Goodman EAG, Gorin A, Grassi M, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Harris DA, Hartz M, Hasegawa T, Hassani S, Hastings NC, Hayato Y, Henaff D, Hiramoto A, Hogan M, Holeczek J, Holin A, Holvey T, Hong Van NT, Honjo T, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishitsuka M, Israel HT, Iwamoto K, Izmaylov A, Izumi N, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang JJ, Jonsson P, Joshi S, Jung CK, Jurj PB, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Kasetti SP, Kataoka Y, Katayama Y, Katori T, Kawaue M, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kikutani H, King S, Kiseeva V, Kisiel J, Kobata T, Kobayashi H, Kobayashi T, Koch L, Kodama S, Konaka A, Kormos LL, Koshio Y, Kostin A, Koto T, Kowalik K, Kudenko Y, Kudo Y, Kuribayashi S, Kurjata R, Kutter T, Kuze M, La Commara M, Labarga L, Lachner K, Lagoda J, Lakshmi SM, Lamers James M, Lamoureux M, Langella A, Laporte JF, Last D, Latham N, Laveder M, Lavitola L, Lawe M, Lee Y, Lin C, Lin SK, Litchfield RP, Liu SL, Li W, Longhin A, Long KR, Lopez Moreno A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Mandal M, Manly S, Marino AD, Marti-Magro L, Martin DGR, Martini M, Martin JF, Maruyama T, Matsubara T, Matveev V, Mauger C, Mavrokoridis K, Mazzucato E, McCauley N, McElwee J, McFarland KS, McGrew C, McKean J, Mefodiev A, Megias GD, Mehta P, Mellet L, Metelko C, Mezzetto M, Miller E, Minamino A, Mineev O, Mine S, Miura M, Molina Bueno L, Moriyama S, Moriyama S, Morrison P, Mueller TA, Munford D, Munteanu L, Nagai K, Nagai Y, Nakadaira T, Nakagiri K, Nakahata M, Nakajima Y, Nakamura A, Nakamura H, Nakamura K, Nakamura KD, Nakano Y, Nakayama S, Nakaya T, Nakayoshi K, Naseby CER, Ngoc TV, Nguyen VQ, Niewczas K, Nishimori S, Nishimura Y, Nishizaki K, Nosek T, Nova F, Novella P, Nugent JC, O’Keeffe HM, O’Sullivan L, Odagawa T, Ogawa T, Okada R, Okinaga W, Okumura K, Okusawa T, Ospina N, Owen RA, Oyama Y, Palladino V, Paolone V, Pari M, Parlone J, Parsa S, Pasternak J, Pavin M, Payne D, Penn GC, Pershey D, Pickering L, Pidcott C, Pintaudi G, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Prabhu YS, Pupilli F, Quilain B, Radermacher T, Radicioni E, Radics B, Ramírez MA, Ratoff PN, Reh M, Riccio C, Rondio E, Roth S, Roy N, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Santucci G, Schloesser CM, Scholberg K, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Skrobova N, Skwarczynski K, Smyczek D, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Speers AJ, Spina R, Suslov IA, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tairafune S, Takayasu S, Takeda A, Takeuchi Y, Takifuji K, Tanaka HK, Tanihara Y, Tani M, Teklu A, Tereshchenko VV, Teshima N, Thamm N, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Vagins M, Vargas D, Varghese M, Vasseur G, Vilela C, Villa E, Vinning WGS, Virginet U, Vladisavljevic T, Wachala T, Walsh JG, Wang Y, Wan L, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wood K, Wret C, Xia J, Xu YH, Yamamoto K, Yamamoto T, Yanagisawa C, Yang G, Yano T, Yasutome K, Yershov N, Yevarouskaya U, Yokoyama M, Yoshimoto Y, Yoshimura N, Yu M, Zaki R, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Zhao X, Zhu T, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S. Measurements of neutrino oscillation parameters from the T2K experiment using 3.6×1021 protons on target. Eur Phys J C Part Fields 2023; 83:782. [PMID: 37680254 PMCID: PMC10480298 DOI: 10.1140/epjc/s10052-023-11819-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 07/10/2023] [Indexed: 09/09/2023]
Abstract
The T2K experiment presents new measurements of neutrino oscillation parameters using 19.7 ( 16.3 ) × 10 20 protons on target (POT) in (anti-)neutrino mode at the far detector (FD). Compared to the previous analysis, an additional 4.7 × 10 20 POT neutrino data was collected at the FD. Significant improvements were made to the analysis methodology, with the near-detector analysis introducing new selections and using more than double the data. Additionally, this is the first T2K oscillation analysis to use NA61/SHINE data on a replica of the T2K target to tune the neutrino flux model, and the neutrino interaction model was improved to include new nuclear effects and calculations. Frequentist and Bayesian analyses are presented, including results on sin 2 θ 13 and the impact of priors on the δ CP measurement. Both analyses prefer the normal mass ordering and upper octant of sin 2 θ 23 with a nearly maximally CP-violating phase. Assuming the normal ordering and using the constraint on sin 2 θ 13 from reactors, sin 2 θ 23 = 0 . 561 - 0.032 + 0.021 using Feldman-Cousins corrected intervals, and Δ m 32 2 = 2 . 494 - 0.058 + 0.041 × 10 - 3 eV 2 using constant Δ χ 2 intervals. The CP-violating phase is constrained to δ CP = - 1 . 97 - 0.70 + 0.97 using Feldman-Cousins corrected intervals, and δ CP = 0 , π is excluded at more than 90% confidence level. A Jarlskog invariant of zero is excluded at more than 2 σ credible level using a flat prior in δ CP , and just below 2 σ using a flat prior in sin δ CP . When the external constraint on sin 2 θ 13 is removed, sin 2 θ 13 = 28 . 0 - 6.5 + 2.8 × 10 - 3 , in agreement with measurements from reactor experiments. These results are consistent with previous T2K analyses.
Collapse
Affiliation(s)
- K. Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - N. Akhlaq
- School of Physics and Astronomy, Queen Mary University of London, London, UK
| | - R. Akutsu
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - A. Ali
- TRIUMF, Vancouver, BC Canada
- Department of Physics, University of Winnipeg, Winnipeg, MB Canada
| | - S. Alonso Monsalve
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - C. Alt
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - C. Andreopoulos
- Department of Physics, University of Liverpool, Liverpool, UK
| | - M. Antonova
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - S. Aoki
- Kobe University, Kobe, Japan
| | - T. Arihara
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
| | - Y. Asada
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - Y. Ashida
- Department of Physics, Kyoto University, Kyoto, Japan
| | - E. T. Atkin
- Department of Physics, Imperial College London, London, UK
| | - M. Barbi
- Department of Physics, University of Regina, Regina, Saskatchewan Canada
| | - G. J. Barker
- Department of Physics, University of Warwick, Coventry, UK
| | - G. Barr
- Department of Physics, Oxford University, Oxford, UK
| | - D. Barrow
- Department of Physics, Oxford University, Oxford, UK
| | | | - F. Bench
- Department of Physics, University of Liverpool, Liverpool, UK
| | - V. Berardi
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - L. Berns
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - S. Bhadra
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Blanchet
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - A. Blondel
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - S. Bolognesi
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - T. Bonus
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
| | - S. Bordoni
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - S. B. Boyd
- Department of Physics, University of Warwick, Coventry, UK
| | - A. Bravar
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - C. Bronner
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - S. Bron
- TRIUMF, Vancouver, BC Canada
| | - A. Bubak
- Institute of Physics, University of Silesia, Katowice, Poland
| | - M. Buizza Avanzini
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - J. A. Caballero
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - N. F. Calabria
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - S. Cao
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
| | - D. Carabadjac
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
- Université Paris-Saclay, Gif-sur-Yvette, France
| | - A. J. Carter
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
| | - S. L. Cartwright
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - M. G. Catanesi
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - A. Cervera
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - J. Chakrani
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - D. Cherdack
- Department of Physics, University of Houston, Houston, TX USA
| | - P. S. Chong
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - G. Christodoulou
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - A. Chvirova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Cicerchia
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
- INFN-Laboratori Nazionali di Legnaro, Legnaro, Italy
| | - J. Coleman
- Department of Physics, University of Liverpool, Liverpool, UK
| | - G. Collazuol
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - L. Cook
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Department of Physics, Oxford University, Oxford, UK
| | - A. Cudd
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - C. Dalmazzone
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - T. Daret
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Yu. I. Davydov
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - A. De Roeck
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - G. De Rosa
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - T. Dealtry
- Physics Department, Lancaster University, Lancaster, UK
| | - C. C. Delogu
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - C. Densham
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A. Dergacheva
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Di Lodovico
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - S. Dolan
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - D. Douqa
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - T. A. Doyle
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - O. Drapier
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - J. Dumarchez
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - P. Dunne
- Department of Physics, Imperial College London, London, UK
| | - K. Dygnarowicz
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - A. Eguchi
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - S. Emery-Schrenk
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - G. Erofeev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Ershova
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - G. Eurin
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - D. Fedorova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S. Fedotov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Feltre
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - A. J. Finch
- Physics Department, Lancaster University, Lancaster, UK
| | | | - G. Fiorillo
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - M. D. Fitton
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - J. M. Franco Patiño
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - M. Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - Y. Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - Y. Fukuda
- Department of Physics, Miyagi University of Education, Sendai, Japan
| | - K. Fusshoeller
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - L. Giannessi
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - C. Giganti
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - V. Glagolev
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - M. Gonin
- ILANCE, CNRS-University of Tokyo International Research Laboratory, Kashiwa, Chiba 277-8582 Japan
| | - J. González Rosa
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - E. A. G. Goodman
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - A. Gorin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Grassi
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - M. Guigue
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - D. R. Hadley
- Department of Physics, University of Warwick, Coventry, UK
| | - J. T. Haigh
- Department of Physics, University of Warwick, Coventry, UK
| | | | - D. A. Harris
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - M. Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- TRIUMF, Vancouver, BC Canada
| | - T. Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - S. Hassani
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - N. C. Hastings
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - Y. Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - D. Henaff
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A. Hiramoto
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M. Hogan
- Department of Physics, Colorado State University, Fort Collins, Colorado USA
| | - J. Holeczek
- Institute of Physics, University of Silesia, Katowice, Poland
| | - A. Holin
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - T. Holvey
- Department of Physics, Oxford University, Oxford, UK
| | - N. T. Hong Van
- International Centre of Physics, Institute of Physics (IOP), Vietnam Academy of Science and Technology (VAST), 10 Dao Tan, Ba Dinh, Hanoi, Vietnam
| | - T. Honjo
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - F. Iacob
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - A. K. Ichikawa
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - M. Ikeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - T. Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - M. Ishitsuka
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
| | - H. T. Israel
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - K. Iwamoto
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A. Izmaylov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N. Izumi
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
| | - M. Jakkapu
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - B. Jamieson
- Department of Physics, University of Winnipeg, Winnipeg, MB Canada
| | - S. J. Jenkins
- Department of Physics, University of Liverpool, Liverpool, UK
| | - C. Jesús-Valls
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - J. J. Jiang
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - P. Jonsson
- Department of Physics, Imperial College London, London, UK
| | - S. Joshi
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C. K. Jung
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - P. B. Jurj
- Department of Physics, Imperial College London, London, UK
| | - M. Kabirnezhad
- Department of Physics, Imperial College London, London, UK
| | - A. C. Kaboth
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - T. Kajita
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - H. Kakuno
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
| | - J. Kameda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - S. P. Kasetti
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - Y. Kataoka
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - Y. Katayama
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - T. Katori
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - M. Kawaue
- Department of Physics, Kyoto University, Kyoto, Japan
| | - E. Kearns
- Department of Physics, Boston University, Boston, MA USA
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - M. Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T. Kikawa
- Department of Physics, Kyoto University, Kyoto, Japan
| | - H. Kikutani
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - S. King
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - V. Kiseeva
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - J. Kisiel
- Institute of Physics, University of Silesia, Katowice, Poland
| | - T. Kobata
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - H. Kobayashi
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - T. Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - L. Koch
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - S. Kodama
- Department of Physics, University of Tokyo, Tokyo, Japan
| | | | - L. L. Kormos
- Physics Department, Lancaster University, Lancaster, UK
| | - Y. Koshio
- Department of Physics, Okayama University, Okayama, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - A. Kostin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T. Koto
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
| | - K. Kowalik
- National Centre for Nuclear Research, Warsaw, Poland
| | - Y. Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Moscow Institute of Physics and Technology (MIPT), Moscow Region, Russia and National Research Nuclear University “MEPhI”, Moscow, Russia
| | - Y. Kudo
- Department of Physics, Yokohama National University, Yokohama, Japan
| | | | - R. Kurjata
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - T. Kutter
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - M. Kuze
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - M. La Commara
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - L. Labarga
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
| | - K. Lachner
- Department of Physics, University of Warwick, Coventry, UK
| | - J. Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | - S. M. Lakshmi
- National Centre for Nuclear Research, Warsaw, Poland
| | - M. Lamers James
- Physics Department, Lancaster University, Lancaster, UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - M. Lamoureux
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - A. Langella
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - J.-F. Laporte
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - D. Last
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - N. Latham
- Department of Physics, University of Warwick, Coventry, UK
| | - M. Laveder
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - L. Lavitola
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - M. Lawe
- Physics Department, Lancaster University, Lancaster, UK
| | - Y. Lee
- Department of Physics, Kyoto University, Kyoto, Japan
| | - C. Lin
- Department of Physics, Imperial College London, London, UK
| | - S.-K. Lin
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - R. P. Litchfield
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - S. L. Liu
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - W. Li
- Department of Physics, Oxford University, Oxford, UK
| | - A. Longhin
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - K. R. Long
- Department of Physics, Imperial College London, London, UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - A. Lopez Moreno
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - L. Ludovici
- INFN Sezione di Roma and Università di Roma “La Sapienza”, Rome, Italy
| | - X. Lu
- Department of Physics, University of Warwick, Coventry, UK
| | - T. Lux
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
| | - L. N. Machado
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - L. Magaletti
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - K. Mahn
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI USA
| | - M. Malek
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - M. Mandal
- National Centre for Nuclear Research, Warsaw, Poland
| | - S. Manly
- Department of Physics and Astronomy, University of Rochester, Rochester, NY USA
| | - A. D. Marino
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - L. Marti-Magro
- Department of Physics, Yokohama National University, Yokohama, Japan
| | | | - M. Martini
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
- IPSA-DRII, Ivry-sur-Seine, France
| | - J. F. Martin
- Department of Physics, University of Toronto, Toronto, ON Canada
| | - T. Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - T. Matsubara
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - V. Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C. Mauger
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - K. Mavrokoridis
- Department of Physics, University of Liverpool, Liverpool, UK
| | - E. Mazzucato
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - N. McCauley
- Department of Physics, University of Liverpool, Liverpool, UK
| | - J. McElwee
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - K. S. McFarland
- Department of Physics and Astronomy, University of Rochester, Rochester, NY USA
| | - C. McGrew
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - J. McKean
- Department of Physics, Imperial College London, London, UK
| | - A. Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G. D. Megias
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - P. Mehta
- Department of Physics, University of Liverpool, Liverpool, UK
| | - L. Mellet
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - C. Metelko
- Department of Physics, University of Liverpool, Liverpool, UK
| | - M. Mezzetto
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - E. Miller
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - A. Minamino
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - O. Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S. Mine
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - M. Miura
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | | | - S. Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - S. Moriyama
- Department of Physics, Yokohama National University, Yokohama, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - P. Morrison
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - Th. A. Mueller
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - D. Munford
- Department of Physics, University of Houston, Houston, TX USA
| | - L. Munteanu
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - K. Nagai
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - Y. Nagai
- Department of Atomic Physics, Eötvös Loránd University, Budapest, Hungary
| | - T. Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - K. Nakagiri
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - M. Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - Y. Nakajima
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A. Nakamura
- Department of Physics, Okayama University, Okayama, Japan
| | - H. Nakamura
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
| | - K. Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- J-PARC, Tokai, Japan
| | - K. D. Nakamura
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - Y. Nakano
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - S. Nakayama
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - T. Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Department of Physics, Kyoto University, Kyoto, Japan
| | - K. Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | | | - T. V. Ngoc
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
- The Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ho Chi Minh City, Vietnam
| | - V. Q. Nguyen
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - K. Niewczas
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
| | - S. Nishimori
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - Y. Nishimura
- Department of Physics, Keio University, Yokohama, Kanagawa Japan
| | - K. Nishizaki
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - T. Nosek
- National Centre for Nuclear Research, Warsaw, Poland
| | - F. Nova
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - P. Novella
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - J. C. Nugent
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | | | - L. O’Sullivan
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - T. Odagawa
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T. Ogawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - R. Okada
- Department of Physics, Okayama University, Okayama, Japan
| | - W. Okinaga
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - K. Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Japan
| | - T. Okusawa
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - N. Ospina
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
| | - R. A. Owen
- School of Physics and Astronomy, Queen Mary University of London, London, UK
| | - Y. Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - V. Palladino
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - V. Paolone
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA USA
| | - M. Pari
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - J. Parlone
- Department of Physics, University of Liverpool, Liverpool, UK
| | - S. Parsa
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - J. Pasternak
- Department of Physics, Imperial College London, London, UK
| | | | - D. Payne
- Department of Physics, University of Liverpool, Liverpool, UK
| | - G. C. Penn
- Department of Physics, University of Liverpool, Liverpool, UK
| | - D. Pershey
- Department of Physics, Duke University, Durham, NC USA
| | - L. Pickering
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
| | - C. Pidcott
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - G. Pintaudi
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - C. Pistillo
- Laboratory for High Energy Physics (LHEP), Albert Einstein Center for Fundamental Physics, University of Bern, Bern, Switzerland
| | - B. Popov
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
- JINR, Dubna, Russia
| | - K. Porwit
- Institute of Physics, University of Silesia, Katowice, Poland
| | | | - Y. S. Prabhu
- National Centre for Nuclear Research, Warsaw, Poland
| | - F. Pupilli
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - B. Quilain
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - T. Radermacher
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - E. Radicioni
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - B. Radics
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - M. A. Ramírez
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - P. N. Ratoff
- Physics Department, Lancaster University, Lancaster, UK
| | - M. Reh
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - C. Riccio
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - E. Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - S. Roth
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - N. Roy
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Rubbia
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - A. C. Ruggeri
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - C. A. Ruggles
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - A. Rychter
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - K. Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - F. Sánchez
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - G. Santucci
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - C. M. Schloesser
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - K. Scholberg
- Department of Physics, Duke University, Durham, NC USA
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - M. Scott
- Department of Physics, Imperial College London, London, UK
| | - Y. Seiya
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
- Science Department, BMCC/CUNY, New York, NY USA
| | - T. Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - H. Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - D. Sgalaberna
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - A. Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Shaker
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Shaykina
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - W. Shorrock
- Department of Physics, Imperial College London, London, UK
| | - A. Shvartsman
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N. Skrobova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - D. Smyczek
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - M. Smy
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
| | - J. T. Sobczyk
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
| | - H. Sobel
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - F. J. P. Soler
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - Y. Sonoda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - A. J. Speers
- Physics Department, Lancaster University, Lancaster, UK
| | - R. Spina
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - I. A. Suslov
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - S. Suvorov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - S. Y. Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - Y. Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - A. A. Sztuc
- Department of Physics, Imperial College London, London, UK
| | - M. Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - S. Tairafune
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - S. Takayasu
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - A. Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - Y. Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kobe University, Kobe, Japan
| | - K. Takifuji
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - H. K. Tanaka
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - Y. Tanihara
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - M. Tani
- Department of Physics, Kyoto University, Kyoto, Japan
| | - A. Teklu
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | | | - N. Teshima
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - N. Thamm
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - L. F. Thompson
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - W. Toki
- Department of Physics, Colorado State University, Fort Collins, Colorado USA
| | - C. Touramanis
- Department of Physics, University of Liverpool, Liverpool, UK
| | - T. Towstego
- Department of Physics, University of Toronto, Toronto, ON Canada
| | - K. M. Tsui
- Department of Physics, University of Liverpool, Liverpool, UK
| | - T. Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - M. Tzanov
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - Y. Uchida
- Department of Physics, Imperial College London, London, UK
| | - M. Vagins
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - D. Vargas
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
| | - M. Varghese
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
| | - G. Vasseur
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C. Vilela
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - E. Villa
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | | | - U. Virginet
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - T. Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J. G. Walsh
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI USA
| | - Y. Wang
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - L. Wan
- Department of Physics, Boston University, Boston, MA USA
| | - D. Wark
- Department of Physics, Oxford University, Oxford, UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - M. O. Wascko
- Department of Physics, Imperial College London, London, UK
| | - A. Weber
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - R. Wendell
- Department of Physics, Kyoto University, Kyoto, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - M. J. Wilking
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - C. Wilkinson
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - J. R. Wilson
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - K. Wood
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - C. Wret
- Department of Physics, Oxford University, Oxford, UK
| | - J. Xia
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - Y.-H. Xu
- Physics Department, Lancaster University, Lancaster, UK
| | - K. Yamamoto
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
- Nambu Yoichiro Institute of Theoretical and Experimental Physics (NITEP), Osaka, Japan
| | - T. Yamamoto
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - C. Yanagisawa
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
- Science Department, BMCC/CUNY, New York, NY USA
| | - G. Yang
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - T. Yano
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - K. Yasutome
- Department of Physics, Kyoto University, Kyoto, Japan
| | - N. Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - U. Yevarouskaya
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - M. Yokoyama
- Department of Physics, University of Tokyo, Tokyo, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - Y. Yoshimoto
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - N. Yoshimura
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M. Yu
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - R. Zaki
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J. Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - K. Zaremba
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - G. Zarnecki
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - X. Zhao
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - T. Zhu
- Department of Physics, Imperial College London, London, UK
| | - M. Ziembicki
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - E. D. Zimmerman
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - M. Zito
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - S. Zsoldos
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - T2K Collaboration
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
- Laboratory for High Energy Physics (LHEP), Albert Einstein Center for Fundamental Physics, University of Bern, Bern, Switzerland
- Department of Physics, Boston University, Boston, MA USA
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
- Department of Physics, Colorado State University, Fort Collins, Colorado USA
- Department of Physics, Duke University, Durham, NC USA
- Department of Atomic Physics, Eötvös Loránd University, Budapest, Hungary
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- Department of Physics, University of Houston, Houston, TX USA
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
- IFIC (CSIC and University of Valencia), Valencia, Spain
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
- Department of Physics, Imperial College London, London, UK
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
- INFN Sezione di Roma and Università di Roma “La Sapienza”, Rome, Italy
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- International Centre of Physics, Institute of Physics (IOP), Vietnam Academy of Science and Technology (VAST), 10 Dao Tan, Ba Dinh, Hanoi, Vietnam
- ILANCE, CNRS-University of Tokyo International Research Laboratory, Kashiwa, Chiba 277-8582 Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Department of Physics, Keio University, Yokohama, Kanagawa Japan
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
- Kobe University, Kobe, Japan
- Department of Physics, Kyoto University, Kyoto, Japan
- Physics Department, Lancaster University, Lancaster, UK
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
- Department of Physics, University of Liverpool, Liverpool, UK
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI USA
- Department of Physics, Miyagi University of Education, Sendai, Japan
- National Centre for Nuclear Research, Warsaw, Poland
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
- Department of Physics, Okayama University, Okayama, Japan
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
- Department of Physics, Oxford University, Oxford, UK
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA USA
- School of Physics and Astronomy, Queen Mary University of London, London, UK
- Department of Physics, University of Regina, Regina, Saskatchewan Canada
- Department of Physics and Astronomy, University of Rochester, Rochester, NY USA
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
- Institute of Physics, University of Silesia, Katowice, Poland
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
- Department of Physics, University of Tokyo, Tokyo, Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Japan
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
- Department of Physics, University of Toronto, Toronto, ON Canada
- TRIUMF, Vancouver, BC Canada
- Faculty of Physics, University of Warsaw, Warsaw, Poland
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
- Department of Physics, University of Warwick, Coventry, UK
- Department of Physics, University of Winnipeg, Winnipeg, MB Canada
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
- Department of Physics, Yokohama National University, Yokohama, Japan
- Department of Physics and Astronomy, York University, Toronto, ON Canada
- Université Paris-Saclay, Gif-sur-Yvette, France
- INFN-Laboratori Nazionali di Legnaro, Legnaro, Italy
- J-PARC, Tokai, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
- Moscow Institute of Physics and Technology (MIPT), Moscow Region, Russia and National Research Nuclear University “MEPhI”, Moscow, Russia
- IPSA-DRII, Ivry-sur-Seine, France
- The Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ho Chi Minh City, Vietnam
- JINR, Dubna, Russia
- Nambu Yoichiro Institute of Theoretical and Experimental Physics (NITEP), Osaka, Japan
- Science Department, BMCC/CUNY, New York, NY USA
| |
Collapse
|
9
|
Morita A, Yagi K, Asakura T, Namkoong H, Sato Y, Ogawa T, Kusumoto T, Suzuki S, Tanaka H, Lee H, Okamori S, Azekawa S, Nakagawara K, Kaji M, Nagao G, Funatsu Y, Kimizuka Y, Kamata H, Nishimura T, Ishii M, Fukunaga K, Hasegawa N. Longitudinal significance of six-minute walk test in patients with nontuberculous mycobacterial pulmonary disease: an observational study. BMC Pulm Med 2023; 23:247. [PMID: 37415094 DOI: 10.1186/s12890-023-02528-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 06/22/2023] [Indexed: 07/08/2023] Open
Abstract
BACKGROUND The long-term exercise tolerance changes in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) are of great interest because of its chronic course. This study aimed to characterize the associations between changes over time in six-minute walking test (6MWT) parameters and clinical parameters in patients with NTM-PD. METHODS Overall, 188 patients with NTM-PD, visiting outpatient clinics at Keio University Hospital from April 2012 to March 2020 were included in the study. Data were collected using the St. George's Respiratory Questionnaire (SGRQ), pulmonary function test (PFT), blood tests, and the 6MWT at registration and at least once after that. The association of the anchors and clinical indicators with the 6MWT parameters was assessed. RESULTS The median age [interquartile range] of the patients was 67 [63-74] years. The median baseline six-minute walk distance (6MWD) and final Borg scale (FBS) were 413 [361-470] m and 1 [0-2], respectively. In the correlation analysis, ΔSGRQ total/year (yr), Δforced vital capacity (FVC, % predicted)/yr, Δforced expiratory volume in 1 s (FEV1, % predicted)/yr, and Δdiffusing capacity for carbon monoxide (DLCO, % predicted)/yr correlated with both Δ6MWD/yr and ΔFBS/yr in the longitudinal analysis (|Rho| > 0.20). When stratified into three quantiles of changes in each anchor, the 6MWT parameters worsened over time in the bottom 25% group by mixed-effects model. Specifically, Δ6MWD was affected by SGRQ activity, SGRQ impacts, PFT (FVC, FEV1, and DLCO), and C-reactive protein (CRP). ΔFBS was affected by all SGRQ components, total score, and PFT. Anchor scores and variables at baseline that worsened Δ6MWD were higher SGRQ scores, lower FVC (% predicted), lower DLCO (% predicted), higher Krebs von den Lungen-6, old age, and undergoing treatment at registration. Similarly, these clinical parameters and elevated CRP, excluding undergoing treatment at registration, worsened ΔFBS. CONCLUSIONS The decreased walking distance and exacerbation of dyspnea on exertion over time in patients with NTM-PD may reflect a deterioration of health-related quality of life and pulmonary function. Thus, the change in 6MWT over time can be used as an indicator to accurately assess the patient's condition and tailor their healthcare environment.
Collapse
Affiliation(s)
- Atsuho Morita
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Kazuma Yagi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
- Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan
- Department of Respiratory Medicine, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan
| | - Ho Namkoong
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
| | - Yasunori Sato
- Department of Preventive Medicine and Public Health, Keio University of Medicine, Tokyo, Japan
| | - Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shoji Suzuki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hiromu Tanaka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Ho Lee
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Satoshi Okamori
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shuhei Azekawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Kensuke Nakagawara
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Masanori Kaji
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Genta Nagao
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Yohei Funatsu
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
- Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan
| | - Yoshifumi Kimizuka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Tomoyasu Nishimura
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
- Keio University Health Center, Tokyo, Japan
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Naoki Hasegawa
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
10
|
Matsukida A, Ogawa T, Tanigaki T, Serizawa Y, Nishimura M, Igarashi S, Kato Y, Kawana A, Kimizuka Y. Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report. Case Rep Oncol 2023; 16:1409-1414. [PMID: 38028574 PMCID: PMC10653709 DOI: 10.1159/000534711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Accepted: 10/16/2023] [Indexed: 12/01/2023] Open
Abstract
Introduction Diffuse lung cysts occur owing to several diseases; however, diffuse cystic lung metastases are very rare in the case of lung cancer. We report a rare case of diffuse cystic lung metastases from lung adenocarcinoma and reviewed previously reported cases of cystic lung metastases for lung cancer and determined their characteristics. Case Presentation A 78-year-old Japanese woman with advanced lung adenocarcinoma was positive for the epidermal growth factor receptor gene mutation exon 21 L858R and had been treated with osimertinib. She presented with multiple bilaterally positioned thin-walled lung cysts and pneumothorax. Lung cysts were diagnosed as cystic lung metastases from lung cancer, and carboplatin, pemetrexed, and pembrolizumab were subsequently administered. All cysts markedly decreased in size, and some disappeared. Conclusion Effective treatment methods for cystic lung metastases from lung cancer have not been reported. To our knowledge, this is the first case of cystic lung metastases that were successfully treated with chemotherapy.
Collapse
Affiliation(s)
- Akira Matsukida
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Takunori Ogawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Tomomi Tanigaki
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Yusuke Serizawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Masashi Nishimura
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Shunya Igarashi
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Yoshiki Kato
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| |
Collapse
|
11
|
Maki Y, Kushibiki T, Sano T, Ogawa T, Komai E, Takahashi S, Kitagami E, Serizawa Y, Nagaoka R, Yokomizo S, Ono T, Ishihara M, Miyahira Y, Kashiwagi S, Kawana A, Kimizuka Y. 1270 nm near-infrared light as a novel vaccine adjuvant acts on mitochondrial photoreception in intradermal vaccines. Front Immunol 2022; 13:1028733. [PMID: 36439134 PMCID: PMC9684730 DOI: 10.3389/fimmu.2022.1028733] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 10/20/2022] [Indexed: 04/13/2024] Open
Abstract
With the development of laser technology in the 1960s, a technique was developed to inject intradermal vaccines immediately after irradiating the skin with laser light to elicit an adjuvant effect, referred to as "laser adjuvant." We have been investigating the mechanism of laser adjuvant in influenza mouse models using noninvasive continuous-wave (CW) near-infrared (NIR) light mainly at a wavelength of 1064 nm, and have shown that the production of reactive-oxygen-species (ROS) in the skin and mast cells in the skin tissue plays an important role in the laser adjuvant effect. The new wavelength of 1270 nm NIR light is characterized by its ability to elicit the same vaccine adjuvant effect as other wavelengths at a lower energy, and may be suitable for clinical applications. In this study, we investigated the physiological activity of CW1270 nm NIR light in mast cells, its biological activity on mouse skin, and the durability of the vaccine adjuvant effect in influenza vaccine mouse models. We show that irradiation of mast cells with 1270 nm NIR light produced ROS and ATP, and irradiation of isolated mitochondria also produced ATP. In mouse skin, the relative expression levels of chemokine mRNAs, such as Ccl2 and Ccl20, were increased by irradiation with 1270 and 1064 nm NIR light at minimum safe irradiance. However, the relative expression of Nfkb1 was increased at 1064 nm, but not at 1270 nm. Serum anti-influenza IgG antibody titers increased early after immunization with 1064 nm, whereas with 1270 nm, there was not only an early response of antibody production but also persistence of antibody titers over the medium- to long-term. Thus, to our knowledge, we show for the first time that 1270 nm NIR light induces ROS and ATP production in mitochondria as photoreceptors, initiating a cascade of laser adjuvant effects for intradermal vaccines. Additionally, we demonstrate that there are wavelength-specific variations in the mechanisms and effects of laser adjuvants. In conclusion, CW1270 nm NIR light is expected to be clinically applicable as a novel laser adjuvant that is equivalent or superior to 1064 nm NIR light, because it can be operated at low energy and has a wavelength-specific adjuvant effect with medium- to long-lasting antibody titer.
Collapse
Affiliation(s)
- Yohei Maki
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Toshihiro Kushibiki
- Department of Medical Engineering, National Defense Medical College, Tokorozawa, Japan
| | - Tomoya Sano
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Takunori Ogawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Eri Komai
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Shusaku Takahashi
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Etsuko Kitagami
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Yusuke Serizawa
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Ryosuke Nagaoka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Shinya Yokomizo
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
- Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, United States
| | - Takeshi Ono
- Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Miya Ishihara
- Department of Medical Engineering, National Defense Medical College, Tokorozawa, Japan
| | - Yasushi Miyahira
- Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Satoshi Kashiwagi
- Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, United States
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
12
|
Shimizu M, Ohwada W, Kouzu H, Sato T, Osanami A, Ogawa T, Ino S, Toda Y, Kuno A, Tanno M, Yano T. Nuclear accumulation of MLKL induces necroptosis in cardiomyocytes: potential implication in Doxorubicin-induced cardiotoxicity. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The treatment with doxorubicin, a powerful chemotherapeutic agent, has been shown to be associated with an increased risk of lethal heart failure. Although various types of cell death pathway such as apoptosis and ferroptosis have been shown to be involved in the development of doxorubicin-induced cardiotoxicity, DIC, the involvement of necroptosis, a novel programmed necrosis induced by translocation of activated mixed lineage kinase domain-like protein, MLKL, to plasma membrane, remains unclear.
Purpose
The aim of this study was to determine whether necroptosis is involved in the development of DIC.
Methods and results
DIC was induced in C57BL/6J mice by intraperitoneal injection of doxorubicin at a dose of 10 mg/kg 3 times for a week. Eight days after the commencement of injection, echocardiographic analyses showed that left ventricular ejection fraction assessed by echocardiography was significantly lower in the doxorubicin-treated mice than in the vehicle-treated mice (44.0±13.7 vs. 70.5±3.7%), indicating the development of DIC. Immunoblot analysis showed that MLKL protein level was higher by 1.6 fold in the doxorubicin-treated mice than in the vehicle-treated mice. Interestingly, immunohistochemical analysis showed that signals of phospho-Ser345-MLKL, an activated form of MLKL, was found in the nuclei in addition to cytosol and intercalated discs of cardiomyocytes in the doxorubicin-treated mice. To get novel insight into significance of nuclear MLKL accumulation, a leucine-rich nuclear export signal (NES) spanning amino acids 280–284 of rat MLKL was identified by site-directed mutation analyses, and H9c2 cells, cultured rat cardiomyoblasts, were transfected with expression constructs for nucleus-directed MLKL (FLAG-mtNES-MLKL) or its wild type (FLAG-WT-MLKL). Percentage of FLAG-positive cells stained with Zombie Red, a fluorescent dye that is non-permeant to live cells, was higher in FLAG-mtNES-MLKL-transfected cells than in FLAG-WT-MLKL-transfected cells (80.0±3.5% vs. 6.3±1.3%, p<0.05), whereas percentage of cells immunostained with cleaved caspase-3 to FLAG-positive cells was similar in the two groups. The effect of the MLKL mutant on necroptosis was attenuated by treatment with GppNHp, an inhibitor of Ran-mediated nuclear protein import.
Conclusion
Nuclear accumulation of MLKL induces necroptosis in cardiomyocytes, which may contribute to progression of DIC.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Shimizu
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - W Ohwada
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - H Kouzu
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - T Sato
- Sapporo Medical University, Department of Cellular Physiology and Signal Transduction , Sapporo , Japan
| | - A Osanami
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - T Ogawa
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - S Ino
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - Y Toda
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - A Kuno
- Sapporo Medical University, Department of Pharmacology , Sapporo , Japan
| | - M Tanno
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| | - T Yano
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine , Sapporo , Japan
| |
Collapse
|
13
|
Morita A, Namkoong H, Yagi K, Asakura T, Hosoya M, Tanaka H, Lee H, Ogawa T, Kusumoto T, Azekawa S, Nakagawara K, Kamata H, Ishii M, Fukunaga K, Ozawa H, Hasegawa N. Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings. Infect Drug Resist 2022; 15:4001-4011. [PMID: 35924016 PMCID: PMC9342928 DOI: 10.2147/idr.s373783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Accepted: 07/13/2022] [Indexed: 11/23/2022] Open
Abstract
Purpose Amikacin liposome inhalation suspension (ALIS), which efficiently allows amikacin to reach the pulmonary periphery for effect while minimising systemic adverse effects, was recently approved for treating Mycobacterium avium complex (MAC) infections. The international Phase 3 open-label clinical trials showed promising results, contributing to sputum culture conversion, but few studies have examined the efficacy and adverse effects of ALIS using real-world data. We identified the clinical outcome and adverse effects of ALIS in the early phase of treatment, for more effective and safe use in clinical practice. Patients and Methods The study population consisted of patients with MAC lung disease (MAC-LD), introduced to ALIS therapy after July 2021 at Keio University Hospital due to poor response to multidrug therapy. The sputum smear/culture results, symptoms, adverse effects, and the serum amikacin concentrations of the early phase of ALIS inhalation therapy were examined. Results A total of 11 patients (9 women; median age 64.6 years) were included in this study. The median disease duration of MAC-LD was 13.7 years, and all patients exhibited a positive culture at the beginning of ALIS inhalation. Three of the six patients (50.0%) who were initially sputum-smear-positive were confirmed to have become sputum-smear-negative within one month, including one culture conversion. ALIS inhalation therapy caused some adverse effects in nine patients (81.8%); however, no serious systemic adverse effects were observed. The most common adverse effect was hoarseness (72.7%), which mostly occurred around 1 week after initiation. The medians of peak serum amikacin concentrations were 1.4 and 2.3 μg/mL for the first and third inhalations, respectively. Trough serum concentrations just before the third inhalation were <1.2 μg/mL in all patients. Conclusion ALIS therapy might be a treatment option for patients with refractory MAC infection with long disease duration and a poor response to guideline-based therapy.
Collapse
Affiliation(s)
- Atsuho Morita
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Ho Namkoong
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
- Correspondence: Ho Namkoong, Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan, Tel +81 03 3353 1211, Fax +81 03 5843 6167, Email
| | - Kazuma Yagi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Makoto Hosoya
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Hiromu Tanaka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Ho Lee
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shuhei Azekawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Kensuke Nakagawara
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hiroyuki Ozawa
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Naoki Hasegawa
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
14
|
Tanaka H, Asakura T, Suzuki S, Okamori S, Kusumoto T, Ogawa T, Uno S, Morita A, Lee H, Namkoong H, Kamata H, Sato Y, Uwamino Y, Nishimura T, Ishii M, Fukunaga K, Hasegawa N. Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study. BMC Pulm Med 2022; 22:202. [PMID: 35596169 PMCID: PMC9123794 DOI: 10.1186/s12890-022-01991-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 05/05/2022] [Indexed: 11/29/2022] Open
Abstract
Background Since nontuberculous mycobacterial pulmonary disease (NTM-PD) is common in middle-aged/elderly slender women at risk of osteoporosis, we hypothesized that NTM-PD could be associated with osteoporosis. The study aimed to evaluate the prevalence of osteoporosis in patients with NTM-PD compared with that in the general population and determine the factors associated with osteoporosis in the subjects, including the serum estradiol (E2) and 25-hydroxyvitamin D (25OHD) levels. Methods We have recruited 228 consecutive adult patients with NTM-PD from a prospective cohort study at the Keio University Hospital, who had no history of osteoporosis or osteoporosis-associated bone fracture but underwent dual-energy X-ray absorptiometry-based bone mineral density (BMD) evaluation from August 2017–September 2019. The E2 and 25OHD levels were measured in 165 patients with available stored serum samples. We performed multivariable logistic regression analyses for osteopenia and osteoporosis. Results Osteoporosis (T-score ≤ − 2.5) and osteopenia (T-score − 1 to − 2.5) were diagnosed in 35.1% and 36.8% of patients with NTM-PD, respectively. Compared with the general population, the proportion of osteoporosis was significantly higher in 50–59-, 60–69-, and 70–79-year-old women with NTM-PD. Multivariable analysis revealed that older age (adjusted odds ratio [aOR] for 1-year increase = 1.12; 95% confidence interval [CI] = 1.07–1.18), female sex (aOR = 36.3; 95% CI = 7.57–174), lower BMI (aOR for 1 kg/m2 decrease = 1.37; 95% CI = 1.14–1.65), and chronic Pseudomonas aeruginosa (PA) infection (aOR = 6.70; 95% CI = 1.07–41.8) were independently associated with osteoporosis. Additionally, multivariable analysis in 165 patients whose serum E2 and 25OHD levels were measured showed that both low E2 levels (< 10 pg/mL) and lower 25OHD levels were independently associated with osteoporosis. Conclusions Middle-aged/elderly women with NTM-PD have a higher prevalence of osteoporosis than the general population. BMD screening should be considered in NTM-PD, especially in older females with severe diseases such as chronic PA infection and lower BMI, and low serum E2 and 25OHD levels. Supplementary Information The online version contains supplementary material available at 10.1186/s12890-022-01991-3.
Collapse
Affiliation(s)
- Hiromu Tanaka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
| | - Shoji Suzuki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Satoshi Okamori
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Shunsuke Uno
- Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Atsuho Morita
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Ho Lee
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Ho Namkoong
- Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Yasunori Sato
- Department of Preventive Medicine and Public Health, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Yoshifumi Uwamino
- Department of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | | | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Naoki Hasegawa
- Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| |
Collapse
|
15
|
Hinoshita F, Katagiri D, Takano H, Ogawa T, Fukaya T, Katsuki T, Takano D, Ejiri S, Nakaya N, Nakahara T, Shinoda T. POS-980 INTERNATIONAL CONTRIBUTION OF JAPAN TO DEVELOP HIGH-LEVEL HEMODIALYSIS IN MALAYSIA. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.1021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
16
|
Ogawa T, Aitake U, Nomura T. Cutaneous arteritis following mRNA‐1273 Moderna COVID‐19 vaccination. J Eur Acad Dermatol Venereol 2022; 36:e399-e400. [DOI: 10.1111/jdv.17947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 01/19/2022] [Indexed: 11/29/2022]
Affiliation(s)
- T. Ogawa
- Department of Dermatology Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan
| | - U. Aitake
- Department of Dermatology Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan
| | - T. Nomura
- Department of Dermatology Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan
| |
Collapse
|
17
|
Ogawa Y, Yano R, Iino R, Kanamori K, Shiozawa Y, Kondo H, Kamimura M, Kisui E, Sakurai S, Ogawa T, Nagamuma A. Nutrition diagnosis and length of hospital stay based on glim criteria. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Shiozawa Y, Naganuma A, Ogawa Y, Yamamoto F, Kimura M, Enokida Y, Ogawa T. Factors predicting skeletal muscle mass loss after gastric cancer surgery: a retrospective observational study. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
19
|
Okamori S, Ishii M, Asakura T, Suzuki S, Namkoong H, Kagawa S, Hegab AE, Yagi K, Kamata H, Kusumoto T, Ogawa T, Takahashi H, Yoda M, Horiuchi K, Hasegawa N, Fukunaga K. ADAM10 partially protects mice against influenza pneumonia by suppressing specific myeloid cell population. Am J Physiol Lung Cell Mol Physiol 2021; 321:L872-L884. [PMID: 34523355 DOI: 10.1152/ajplung.00619.2020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The influenza virus infection poses a serious health threat worldwide. Myeloid cells play pivotal roles in regulating innate and adaptive immune defense. A disintegrin and metalloproteinase (ADAM) family of proteins contributes to various immune responses; however, the role of a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) in influenza virus infection remains largely unknown. Herein, we investigated its role, focusing on myeloid cells, during influenza virus infection in mice. ADAM10 gene (Adam10)flox/flox/Lyz2-Cre (Adam10ΔLyz2) and control Adam10flox/flox mice were intranasally infected with 200 plaque-forming units of influenza virus A/H1N1/PR8/34. Adam10ΔLyz2 mice exhibited a significantly higher mortality rate, stronger lung inflammation, and a higher virus titer in the lungs than control mice. Macrophages and inflammatory cytokines, such as TNF-α, IL-1β, and CCL2, were increased in bronchoalveolar lavage fluid from Adam10ΔLyz2 mice following infection. CD11b+Ly6G-F4/80+ myeloid cells, which had an inflammatory monocyte/macrophage-like phenotype, were significantly increased in the lungs of Adam10ΔLyz2 mice. Adoptive transfer experiments suggested that these cells likely contributed to the poorer prognosis in Adam10ΔLyz2 mice. Seven days after infection, CD11b+Ly6G-F4/80+ lung cells exhibited significantly higher arginase-1 expression levels in Adam10ΔLyz2 mice than in control mice, whereas an arginase-1 inhibitor improved the prognosis of Adam10ΔLyz2 mice. Enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF)/GM-CSF receptor signaling likely contributed to this process. Collectively, these results indicate that myeloid ADAM10 protects against influenza virus pneumonia and may be a promising therapeutic target.
Collapse
Affiliation(s)
- Satoshi Okamori
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.,Japan Society of Promotion of Science, Tokyo, Japan
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shoji Suzuki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Ho Namkoong
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shizuko Kagawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Ahmed E Hegab
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.,Medical Education Center, School of Medicine, International University of Health and Welfare, Chiba, Japan
| | - Kazuma Yagi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hayato Takahashi
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - Masaki Yoda
- Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Keisuke Horiuchi
- Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.,Department of Orthopedic Surgery, National Defence Medical College, Saitama, Japan
| | - Naoki Hasegawa
- Center for Infectious Diseases and Infection Control, Keio University School of Medicine, Tokyo, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
20
|
Ogawa T, Kouzu H, Osanami A, Tatekoshi Y, Oshima H, Mizuno M, Kuno A, Fujita Y, Ino S, Shimizu M, Ohwada W, Sato T, Yano T, Tanno M, Miura T. Intracellular localization of AMP deaminase and its novel role in BCAA and lipid metabolism in diabetic cardiomyopathy. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
A metabolomic study in the human heart suggested a pivotal role of amino acid (AA) metabolism in fatty acid oxidation, which is dysregulated in type 2 diabetes mellitus (T2DM) and heart failure. We previously reported that aberrant up-regulation of AMP deaminase 3 (AMPD3) impairs cardiac energetics in T2DM hearts, and AMPD3 was recently shown to be activated by fasting and to promote AA metabolism and fatty acid oxidation in skeletal muscle. A sodium glucose cotransporter 2 inhibitor (SGLT2i) has been shown to augment systemic AA metabolism, but its effect on cardiac AA metabolism remains unknown.
Purpose
We hypothesized that AMPD3 has a role in AA and lipid metabolism in cardiomyocytes and that the protective effect of an SGLT2i in diabetic hearts is mediated by modification of AA and lipid metabolism.
Methods and results
Proteomic analyses of AMPD3 immunoprecipitates in rat hearts revealed that AMPD3 interacted with the E1α and E2 components of the BCKDH complex, a rate-limiting enzyme of branched-chain AA (BCAA) catabolism. Immunoblotting using subcellular fractions revealed that BCKDH localized not only in the mitochondria matrix but also in the cytosol and endoplasmic reticulum (ER) and that AMPD3 interacted with BCKDH in the cytosol and ER. Despite comparable expression of BCKDH components and phosphorylation of E1α at Ser293, significant accumulation of BCAA was observed in T2DM rats (OLETF; 317±30 nmol/g) compared to that in control rats (LETO; 213±16 nmol/g), and the accumulation of BCAA was accompanied by up-regulation of AMPD3 in the cytosol and ER by 98% and 231%, respectively. In cardiomyocytes, disruption of BCAA catabolism by knockdown of BCKDH-E1α resulted in a 5.8-fold increase in AMPD3 at the transcriptional level and blunted lipid droplet biogenesis in response to a long-chain fatty acid challenge. Next, myocardial infarction (MI) was induced in LETO and OLETF pretreated with empagliflozin (10 mg/kg/day, 14 days) or a vehicle. Pathway analysis of cardiac metabolites revealed arginine biosynthesis and BCAA metabolism as the most significantly changed pathways with empagliflozin, with BCAA (791±187 nmol/g), glutamate, glutamine and urea being significantly increased. Empagliflozin restored myocardial ATP and survival after MI in OLETF to levels comparable to those in LETO. Electron microscopy showed a significantly higher prevalence of myocardium lipid droplets in OLETF, which was further increased by empagliflozin.
Conclusions
The results support the hypotheses that imbalance of extra-mitochondrial AMPD3-BCKDH interaction underlies dysregulated BCAA metabolism in T2DM hearts and that activation of cardiac AA metabolism by an SGLT2i normalizes fatty acid overload through sequestration into intracellular lipid droplets.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Boehringer Ingelheim
Collapse
Affiliation(s)
- T Ogawa
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - H Kouzu
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - A Osanami
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - Y Tatekoshi
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - H Oshima
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - M Mizuno
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - A Kuno
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - Y Fujita
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - S Ino
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - M Shimizu
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - W Ohwada
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Sato
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Yano
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - M Tanno
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Miura
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| |
Collapse
|
21
|
Hasani-Sadrabadi MM, Pouraghaei S, Zahedi E, Sarrion P, Ishijima M, Dashtimoghadam E, Jahedmanesh N, Ansari S, Ogawa T, Moshaverinia A. Antibacterial and Osteoinductive Implant Surface Using Layer-by-Layer Assembly. J Dent Res 2021; 100:1161-1168. [PMID: 34315313 PMCID: PMC8716140 DOI: 10.1177/00220345211029185] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Osseointegration of dental, craniofacial, and orthopedic implants is critical for their long-term success. Multifunctional surface treatment of implants was found to significantly improve cell adhesion and induce osteogenic differentiation of dental-derived stem cells in vitro. Moreover, local and sustained release of antibiotics via nanolayers from the surface of implants can present unparalleled therapeutic benefits in implant dentistry. Here, we present a layer-by-layer surface treatment of titanium implants capable of incorporating BMP-2-mimicking short peptides and gentamicin to improve their osseointegration and antibacterial features. Additionally, instead of conventional surface treatments, we employed polydopamine coating before layer-by-layer assembly to initiate the formation of the nanolayers on rough titanium surfaces. Cytocompatibility analysis demonstrated that modifying the titanium implant surface with layer-by-layer assembly did not have adverse effects on cellular viability. The implemented nanoscale coating provided sustained release of osteoinductive peptides with an antibacterial drug. The surface-functionalized implants showed successful osteogenic differentiation of periodontal ligament stem cells and antimicrobial activity in vitro and increased osseointegration in a rodent animal model 4 wk postsurgery as compared with untreated implants. Altogether, our in vitro and in vivo studies suggest that this approach can be extended to other dental and orthopedic implants since this surface functionalization showed improved osseointegration and an enhanced success rate.
Collapse
Affiliation(s)
- M M Hasani-Sadrabadi
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
- California NanoSystems Institute, University of California, Los Angeles, CA, USA
- Department of Bioengineering, University of California, Los Angeles, CA, USA
| | - S Pouraghaei
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
| | - E Zahedi
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
| | - P Sarrion
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
| | - M Ishijima
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
| | - E Dashtimoghadam
- Department of Chemistry, University of North Carolina, Chapel Hill, NC, USA
| | - N Jahedmanesh
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
| | - S Ansari
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
| | - T Ogawa
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
| | - A Moshaverinia
- Weintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, CA, USA
- California NanoSystems Institute, University of California, Los Angeles, CA, USA
| |
Collapse
|
22
|
Komeya M, Odaka H, Matsumura T, Yamanaka H, Sato T, Yao M, Masumori N, Ogawa T. P–017 The maintenance of testicular architecture and germ cell in adult testis tissue under organ culture condition based on the gas-liquid interface method. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Can the gas-liquid interface organ culture system that achieved in vitro spermatogenesis in mice also support in vitro spermatogenesis in human adult testis?
Summary answer
Although the progression of spermatogenesis was not observed, germ cells were maintained without the degeneration of the architecture in both fresh and cryopreserved testicular tissues.
What is known already
Although the research on in vitro spermatogenesis have been conducted for 100 years, only the organ culture system using gas-liquid interface method achieved in vitro spermatogenesis in mice. It has not been verified whether this culture system can be applied to other mammals including humans and induce spermatogenesis.
Study design, size, duration
Testicular tissue was obtained from the transgender patients receiving sex reassignment surgery. Testicular specimens were either immediately processed for cultivation or cryopreserved, using a vitrification freezing protocol. Organ culture of testicular fragments was performed in three different media for a maximum period of 3 weeks to evaluate the short-term changes in the cultured tissues (viability, proliferation and maintenance of germ and somatic cells).
Participants/materials, setting, methods
Fresh and cryopreserved-thawed testis fragments (1–2 mm3) were cultured using the organ culture system in alpha-MEM with knock-out serum replacement (K group), alpha-MEM with lipid-rich BSA (A group) and DMEM with FBS (D group). Luteinizing hormone, follicle stimulating hormone and testosterone were supplemented. The number of germ cells (using DDX4), proliferative activity of germ cells (using EdU assay) and intratubular cell apoptosis (by TdT-mediated dUTP Nick End Labeling) were evaluated by immunohistochemical staining weekly.
Main results and the role of chance
The architecture of the seminiferous tubules was maintained until the second week of culture in both the fresh and the cryopreserved culture group. The number of DDX4-positive germ cells per seminiferous tubule in groups D, K, and A was 49 ± 24, 55 ± 21, 50 ± 26 cells/tubule in 1 day, 32 ± 13, 42 ± 7, 36 ± 21 cells/tubule in 1week, respectively. The numbers gradually decreased to 26 ± 8, 24 ± 6 and 27 ± 18 cells/tubule, in 2 weeks, respectively, with no difference among the groups. The number of intratubular EdU-positive cells of groups D, K, and A was 0.2 ± 0.2, 2.8 ± 2.1, 1.1 ± 0.8 cells/tubule at 1 day, 0.1 ± 0.2, 0.5 ± 0.6, 0.3 ± 0.6 cells/tubule at 1 week, respectively. The values were 0.01, 0.05, and 0.03 at 2 weeks. Thus, EdU-positive cells drastically decreased from the first week of culture. The number of DDX4-positive germ cells and the intratubular EdU-positive cells in the cryopreserved culture group was not different from that in the fresh culture group.
Limitations, reasons for caution
Current organ culture systems are incomplete, being unable to induce human in vitro spermatogenesis. Further research is needed to improve culture condition with the aim of producing fertile sperm of infertile adult male patients.
Wider implications of the findings: Our organ culture system could maintain testis structure and germ cells. By using the testis tissues of the transgender patients, which are available with their consent, we will promote the investigation of the culture condition necessary for germ cell proliferation and differentiation.
Trial registration number
Grant-in-Aid for Scientific Research on Innovative Areas 18H05546, Grant-in-Aid for Young Scientists (A) 17H05098 and Takeda Science Foundation
Collapse
Affiliation(s)
- M Komeya
- Yokohama City University Graduate School of Medicine, Urology, Yokohama, Japan
| | - H Odaka
- Yokohama City University Graduate School of Medicine, Urology, Yokohama, Japan
| | - T Matsumura
- Yokohama City University Association of Medical Science, Laboratory of Biopharmaceutical and Regenerative Sciences- Institute of Molecular Medicine and Life Science, Yokohama, Japan
| | - H Yamanaka
- Yokohama City University Graduate School of Medicine, Urology, Yokohama, Japan
| | - T Sato
- Yokohama City University Association of Medical Science, Laboratory of Biopharmaceutical and Regenerative Sciences- Institute of Molecular Medicine and Life Science, Yokohama, Japan
| | - M Yao
- Yokohama City University Graduate School of Medicine, Urology, Yokohama, Japan
| | - N Masumori
- Sapporo Medical University, Urology, Sapporo, Japan
| | - T Ogawa
- Yokohama City University Association of Medical Science, Laboratory of Biopharmaceutical and Regenerative Sciences- Institute of Molecular Medicine and Life Science, Yokohama, Japan
| |
Collapse
|
23
|
Abstract
After the accident at Fukushima Daiichi nuclear power plant on 11 March 2011, radioactive materials were released into the atmosphere resulting in environmental contamination. Following the implementation of environmental decontamination efforts, the Radiation Dose Registration Centre of the Radiation Effects Association established the radiation dose registration system for decontamination and related workers to consolidate and prevent the loss of radiation records. This article presents statistics on the radiation doses of decontamination and related workers using official records. Since approximately 10 years have passed since the accident in Fukushima, the types of work conducted in the affected restricted areas have changed over time. Therefore, changes in radiation dose for each type of work and comparisons with nuclear workers are presented.
Collapse
Affiliation(s)
- T Ogawa
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - T Ueno
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - T Asano
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - A Suzuki
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - A Ito
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| |
Collapse
|
24
|
Ogawa T, Koike M, Nakahama M, Kato S. Poor Oral Health Is a Factor that Attenuates the Effect of Rehabilitation in Older Male Patients with Fractures. J Frailty Aging 2021; 11:324-328. [DOI: 10.14283/jfa.2021.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
25
|
Naganuma A, Horiguchi S, Suzuki Y, Hoshino T, Ogawa Y, Inagawa M, Ogawa T, Sato K, Kakizaki S. Benefit of zinc acetate administration in patients with noncompensated liver cirrhosis with hypozincemia: a retrospective observational study. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Ogawa Y, Naganuma A, Kudou T, Hoshino T, Ishii K, Kishi A, Shimoda C, Masuda T, Ogawa T, Ishihara H. Relationship between sarcopenia and length of hospital stay in patients with ulcerative colitis. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Igaki Y, Osanami A, Tanno M, Sato T, Ogawa T, Yano T, Kouzu H, Miura T. Inhibition of xanthine oxidase ameliorates functional and metabolic impairment in type 2 diabetic hearts under pressure overload. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
We recently reported that upregulated AMP deaminase (AMPD), via reduction in the tissue adenine nucleotide pool, contributes to exacerbation of diastolic dysfunction under pressure overload in OLETF, a rat model of obese type 2 diabetes (T2DM). Upregulated AMPD also possibly promotes xanthine oxidase (XO)-mediated ROS production, since AMPD deaminases AMP to IMP, which is further converted to inosine, providing substrates of XO, hypoxanthine and xanthine. Here, we examined the hypothesis that inhibition of XO ameliorates the pressure overload-induced diastolic dysfunction by suppression of ROS-mediated mitochondrial dysfunction and/or vascular dysfunction in T2DM rats.
Methods and results
Metabolomic analyses revealed that levels of xanthine and uric acid in the LV myocardium were significantly higher by 37% and 51%, respectively, in OLETF than in LETO, non-diabetic control rats, under the condition of phenylephrine-induced pressure overloading (200–230 mmHg). Myocardial XO activity in OLETF was 57.9% higher than that in LETO, which may be attributed to 31% higher level of inosine, a positive regulator of XO, in OLETF than in LETO. The activity of XO was significantly attenuated by administration of topiroxostat, an XO inhibitor at 0.5 mg/kg/day for 14 days. Pressure volume loop analyses showed that the pressure overloading resulted in significantly higher LVEDP in OLETF than in LETO (18.3±1.5 vs. 12.2±1.3 mmHg, p<0.05, n=7), though LVEDPs at baseline were comparable in OLETF and LETO (5.6±0.4 vs. 4.7±0.7 mmHg). Treatment with topiroxostat significantly suppressed the pressure overload-induced elevation of LVEDP in OLETF (18.3±1.5 vs. 11.3±1.1 mmHg, p<0.05) but not in LETO. Under the condition of pressure overloading, Ea/Ees, an index for ventricular-arterial coupling, was higher in OLETF than in LETO (2.3±0.3 vs. 1.6±0.3, p<0.05), and it was also improved by topiroxostat in OLETF (1.2±0.2, p<0.05). Myocardial ATP content was lower in OLETF than in LETO (2966±400 vs. 1818±171 nmol/g wet tissue, p<0.05), and treatment with topiroxostat significantly restored the ATP level (2629±307 nmol/g wet tissue). The LV myocardium of OLETF under pressure overload showed significantly higher level of malondialdehyde and 4-hydroxynonenal, an indicator of lipid peroxidation, than that of LETO. Measurement of oxygen consumption rate by Seahorse XFe96 Analyzer in mitochondria isolated from LV tissues revealed that state 3 respiration was significantly suppressed in OLETF by 43% compared to LETO, and it was restored by treatment with topiroxostat.
Conclusion
Both activity and substrates of XO are increased in T2DM hearts, in which upregulation of AMPD may play a role. Inhibition of XO ameliorates pressure overload-induced diastolic dysfunction and improves ventricular-arterial coupling in diabetic hearts, most likely through protection of mitochondrial function from ROS-mediated injury.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Grant-in-aid for Scientific Research (#26461132, #17K09584) from the Japanese Society for the Promotion of Science
Collapse
Affiliation(s)
- Y Igaki
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - A Osanami
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - M Tanno
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Sato
- Sapporo Medical University, Department of Cellular physiology and Signal Transduction, Sapporo, Japan
| | - T Ogawa
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Yano
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - H Kouzu
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Miura
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| |
Collapse
|
28
|
Yokota T, Zenda S, Ota I, Yamazaki T, Yamaguchi T, Ogawa T, Tachibana H, Toshiyasu T, Homma A, Miyaji T, Mashiko T, Hamauchi S, Tominaga K, Ishii S, Otani Y, Orito N, Uchitomi Y. 931P Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: A phase III, randomized, double-blinded trial: J-SUPPORT 1602(TOPICS). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
29
|
Ogawa T, Miyata J, Maehara J, Inoue T, Betsuyaku T. Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC. J Thorac Oncol 2020; 14:e9-e10. [PMID: 30579555 DOI: 10.1016/j.jtho.2018.09.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 09/02/2018] [Accepted: 09/03/2018] [Indexed: 10/27/2022]
Affiliation(s)
- Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Respiratory Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Jun Miyata
- Department of Respiratory Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan; Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
| | - Junki Maehara
- Department of Pathology, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Takashi Inoue
- Department of Respiratory Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Tomoko Betsuyaku
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
30
|
Miyata J, Ogawa T, Tagami Y, Sato T, Nagayama M, Hirano T, Kameyama N, Fukunaga K, Kawana A, Inoue T. Serum soluble interleukin-2 receptor level is a predictive marker for EBUS-TBNA-based diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37:8-16. [PMID: 33093764 PMCID: PMC7569541 DOI: 10.36141/svdld.v37i1.8313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 11/25/2019] [Indexed: 12/19/2022]
Abstract
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a widely available diagnostic tool for suspected stage I/II sarcoidosis. Combination of EBUS-TBNA and transbronchial lung biopsy (TBLB) has been proposed as diagnostic procedure in clinical settings. Objectives: The aim of this study was to assess the diagnostic yield of combined EBUS-TBNA and TBLB and identify the markers correlated with a high diagnostic rate. Methods: We retrospectively analyzed the data of 37 patients with suspected stage I/II sarcoidosis with enlarged hilar or mediastinal lymph nodes on computed tomography (CT) images. These patients had been scheduled to undergo EBUS-TBNA and TBLB. Serum levels of sarcoidosis markers (angiotensin-converting enzyme [ACE], soluble interleukin-2 receptor [sIL-2R], and lysozyme), CT findings, and examination techniques were evaluated as predictive markers for diagnosis. Results: Of the 37 patients, 32 had undergone both EBUS-TBNA and TBLB, while the remaining 5 patients had only undergone EBUS-TBNA. The diagnosis was confirmed by TBLB in 16 of the 32 patients (50.0%), EBUS-TBNA in 31 of the 37 patients (83.8%), and combined TBLB and EBUS-TBNA in all patients (100.0%). The serum level of sIL-2R, but not that of ACE or lysozyme, was correlated with successful diagnosis by EBUS-TBNA. Conclusion: In patients with stage I/II sarcoidosis, the serum level of sIL-2R is a promising and useful marker for predicting the diagnosis by EBUS-TBNA and reducing the burden of additional TBLB and its possible complications. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (1): 8-16)
Collapse
Affiliation(s)
- Jun Miyata
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.,Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Takunori Ogawa
- Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan.,Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Yoichi Tagami
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Takashi Sato
- Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Mikie Nagayama
- Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Toshiyuki Hirano
- Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Naofumi Kameyama
- Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Takashi Inoue
- Department of Pulmonary Medicine, Sano Kosei General Hospital, Sano, Tochigi, Japan
| |
Collapse
|
31
|
Naganuma A, Tateyama Y, Taira T, Shibasaki E, Murakami T, Masuda T, Uehara S, Yasuoka H, Hoshino T, Kudo T, Ishihara H, Ogawa Y, Shimizu T, Ishii K, Inagawa M, Tanaka T, Ogawa T, Oishi H. SUN-PO265: Usefulness of Nutrition Management by Percutaneous Trans-Esophageal Gastro-Tubing. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32895-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Ogawa Y, Naganuma A, Inagawa M, Kimura M, Kanai M, Yoshida T, Kaneda T, Morohoshi A, Shimoda C, Sakamoto K, Manome M, Noguchi K, Tanaka T, Ogawa T, Ishihara H. MON-PO629: Indications for Percutaneous Endoscopic Gastrostomy in Patients with Acute Cerebral Infarction. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32462-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Nishida Y, Takahashi YK, Kanai T, Nose Y, Ishibashi S, Sanjo N, Uzawa A, Oda F, Ozawa Y, Kuwabara S, Noguchi E, Suzuki S, Nakahara J, Suzuki N, Ogawa T, Yokoyama K, Hattori N, Konno S, Fujioka T, Kawaguchi N, Hatanaka Y, Sonoo M, Kaneko J, Ogino M, Nishiyama K, Nomura K, Yokota T. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis. Eur J Neurol 2019; 27:100-104. [PMID: 31309642 DOI: 10.1111/ene.14039] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Accepted: 07/10/2019] [Indexed: 01/09/2023]
Abstract
BACKGROUND AND PURPOSE Tapering immunosuppressants is desirable in patients with well-controlled myasthenia gravis (MG). However, the association between tapering of calcineurin inhibitor dosage and reduction-associated exacerbation is not known. The aim of this study was to clarify the frequency of reduction-associated exacerbation when tacrolimus is tapered in stable patients with anti-acetylcholine receptor antibody-positive MG, and to determine the factors that predict exacerbations. METHODS We retrospectively analyzed 115 patients in whom tacrolimus dosage was tapered. The reduction-associated exacerbation was defined as the appearance or worsening of one or more MG symptoms <3 months after the reduction. RESULTS Tacrolimus dosage was successfully tapered in 110 patients (96%) without any exacerbation. Five patients (4%) experienced an exacerbation, but symptoms were reversed in all patients when the tacrolimus dose was increased to the previous maintenance level. No patient developed an MG crisis. The age at onset was significantly earlier (30 vs. 56 years, P = 0.025) and the reduction in dosage was significantly larger (2.0 vs. 1.0 mg/day, P = 0.002) in patients with reduction-associated exacerbation than in those without exacerbation. The cut-off values determined in a receiver-operating characteristic curve analysis were 52 years (sensitivity, 57%; specificity, 100%) for the age at onset and 1.5 mg (sensitivity, 80%; specificity, 100%) for the dose reduction. CONCLUSION Tapering of tacrolimus was possible in most patients with well-controlled anti-acetylcholine receptor antibody-positive MG. Early age at onset and a large reduction from maintenance dosage were associated with exacerbation. Reductions ≤1.5 mg/day from the maintenance dosage should be considered for patients with late-onset disease.
Collapse
Affiliation(s)
- Y Nishida
- Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Y K Takahashi
- Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - T Kanai
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Nose
- Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Ishibashi
- Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - N Sanjo
- Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - A Uzawa
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - F Oda
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Ozawa
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - S Kuwabara
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - E Noguchi
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan
| | - S Suzuki
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan
| | - J Nakahara
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan
| | - N Suzuki
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan
| | - T Ogawa
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - K Yokoyama
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - N Hattori
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - S Konno
- Department of Neurology, Toho University Ohashi Medical Center, Tokyo, Japan
| | - T Fujioka
- Department of Neurology, Toho University Ohashi Medical Center, Tokyo, Japan
| | | | - Y Hatanaka
- Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan
| | - M Sonoo
- Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan
| | - J Kaneko
- Department of Neurology, Kitasato University School of Medicine, Kanagawa, Japan
| | - M Ogino
- School of Medicine, Center for Medical Education, International University of Health and Welfare, Chiba, Japan
| | - K Nishiyama
- Department of Neurology, Kitasato University School of Medicine, Kanagawa, Japan
| | - K Nomura
- Department of Neurology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
| | - T Yokota
- Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
34
|
Ogawa T, Tanaka K, Ohgino K, Omori N, Betsuyaku T, Sayama K. Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases. J Infect Chemother 2019; 25:1043-1046. [PMID: 31178281 DOI: 10.1016/j.jiac.2019.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2018] [Revised: 04/15/2019] [Accepted: 05/15/2019] [Indexed: 10/26/2022]
Abstract
Laninamivir, a neuraminidase inhibitor (NAI), has been used for the treatment and prophylaxis of influenza A/B. To date, pneumonia has not been reported as an adverse effect of NAIs. Here, we report the first 2 cases of drug-induced pneumonitis after the administration of laninamivir octanoate (LO), a pro-drug of laninamivir. Case 1 reports a 20-year-old healthy woman presenting with LO-induced pneumonitis so severe that it was necessary for endotracheal intubation and administration of mechanical ventilator support. Steroids were used for the treatment of pneumonitis and rapid improvement was observed. Case 2 reports a 35-year-old healthy woman presenting with less severe LO-induced pneumonitis that improved without any treatment. In both cases, drug-induced lymphocyte stimulation tests (DLSTs) were positive. In the bronchoalveolar lavage (BAL) fluid, the proportion of eosinophils to lymphocytes was higher in Case 1. Conversely, the proportion of lymphocytes to eosinophils was higher in Case 2. Collectively, we determined 3 clinical issues: (1) LO could cause pneumonia; (2) BAL and DLST could be helpful in the diagnosis of LO-induced pneumonitis; and (3) LO-induced pneumonia could become severe, though steroids were effective in improving it.
Collapse
Affiliation(s)
- Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kanagawa, Japan
| | | | | | - Nao Omori
- Kawasaki Municipal Hospital, Kanagawa, Japan
| | - Tomoko Betsuyaku
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | | |
Collapse
|
35
|
Saito T, Minagawa T, Ogawa T, Ishizuka O. Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients. Journal of Clinical Urology 2019. [DOI: 10.1177/2051415818817127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Objectives: This study was performed to evaluate the effects of addition of tadalafil to tamsulosin in the treatment of brachytherapy patients with lower urinary tract symptoms (LUTS). Methods: Localized prostate cancer patients who developed LUTS after low-dose-rate brachytherapy (LDR-BT) were first treated with alpha-1 blockers (tamsulosin, 0.2 mg per day). Those still suffering from LUTS were additionally treated with phosphodiesterase type 5 inhibitor (tadalafil, 5 mg/day). LUTS was evaluated by the International Prostate Symptom Score (IPSS), IPSS Quality of Life (QOL) score, Overactive Bladder Symptom Score (OABSS), and the International Index of Erectile Function 5 (IIEF5) score before brachytherapy, before treatment with tadalafil, and after three months of treatment with tadalafil. Results: Twenty-three patients were enrolled in the study. Each subscore of the IPSS (storage symptom, voiding symptom, and postvoiding symptom) and the QOL score improved, but OABSS and IIEF5 did not show significant recovery after addition of tadalafil treatment. When patient characteristics and each question score were surveyed, time from seed implantation until treatment with tadalafil showed the strongest correlation with recovery. Conclusions: Addition of tadalafil to tamsulosin treatment was effective against LUTS in localised prostate cancer patients after brachytherapy. Evidence level: 2b
Collapse
Affiliation(s)
- T Saito
- Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Minagawa
- Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan
| | - T Ogawa
- Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan
| | - O Ishizuka
- Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan
| |
Collapse
|
36
|
Ogawa T, Ishitsuka Y, Roop D, Fujimoto M. 314 Loricrin protects against chemical carcinogenesis but affects cancer immunoediting. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Asakura T, Suzuki S, Fukano H, Okamori S, Kusumoto T, Uwamino Y, Ogawa T, So M, Uno S, Namkoong H, Yoshida M, Kamata H, Ishii M, Nishimura T, Hoshino Y, Hasegawa N. Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease. Open Forum Infect Dis 2019; 6:ofz108. [PMID: 31111076 PMCID: PMC6519390 DOI: 10.1093/ofid/ofz108] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Accepted: 03/01/2019] [Indexed: 02/05/2023] Open
Abstract
Background Sitafloxacin (STFX) exhibits potent activity against Mycobacterium avium complex (MAC) in both in vitro and in vivo experiments. However, limited data are available for the clinical efficacy and adverse effects of STFX and the susceptibility of refractory MAC lung disease (MAC-LD) to the drug. Therefore, this study was aimed at evaluating the clinical efficacy and safety of an STFX-containing regimen for the treatment of refractory MAC-LD. Methods We retrospectively evaluated treatment outcomes of 31 patients with refractory MAC-LD, who received an STFX-containing regimen for ≥4 weeks between January 2010 and July 2017. Refractory MAC-LD was defined as persistent positive sputum cultures for >6 months of macrolide-based standard therapy. Results Clarithromycin resistance (minimum inhibitory concentration [MIC] ≥32 μg/mL) was identified in 15 patients (48%). Twelve months after receiving the STFX-containing regimen, 26% and 19% of patients showed symptomatic and radiological responses, respectively. Although STFX-associated adverse effects were noted in 9 patients, their severity was grade 1 (National Cancer Institute Common Terminology Criteria); only 1 patient discontinued STFX because of suspected gastrointestinal disturbance. Negative sputum culture conversion was achieved in 7 patients (23%). Both univariate and multivariate logistic regression analyses revealed that surgery, low STFX MIC (≤1 μg/mL), and macrolide resistance were significant predictors of negative sputum culture conversion. Conclusions Our results demonstrate that STFX may be effective in one-fourth of patients with refractory MAC-LD. Prospective larger studies that include the analyses of MAC are needed to determine the clinical efficacy of STFX against refractory MAC-LD.
Collapse
Affiliation(s)
- Takanori Asakura
- Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases.,Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine.,Japan Society for the Promotion of Science, Tokyo
| | - Shoji Suzuki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine.,Japan Society for the Promotion of Science, Tokyo
| | - Hanako Fukano
- Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases
| | - Satoshi Okamori
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine.,Japan Society for the Promotion of Science, Tokyo
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
| | - Yoshifumi Uwamino
- Department of Laboratory Medicine, Keio University School of Medicine
| | - Takunori Ogawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
| | - Matsuo So
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
| | - Shunsuke Uno
- Center for Infectious Diseases and Infection Control, Keio University School of Medicine
| | - Ho Namkoong
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
| | - Mitsunori Yoshida
- Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
| | | | - Yoshihiko Hoshino
- Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases
| | - Naoki Hasegawa
- Center for Infectious Diseases and Infection Control, Keio University School of Medicine
| |
Collapse
|
38
|
Ogawa T, Inoue S, Inada M, Kawaguchi M. Postoperative intensive care unit admission does not affect outcomes in elective surgical patients with severe comorbidity. Med Intensiva 2019; 44:216-225. [PMID: 30799043 DOI: 10.1016/j.medin.2019.01.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 01/08/2019] [Accepted: 01/09/2019] [Indexed: 01/29/2023]
Abstract
OBJECTIVE The impact of postoperative intensive care upon patient outcomes was evaluated by retrospectively investigating the rate of poor outcomes among miscellaneous elective surgical patients with severe comorbidities. DESIGN A retrospective cohort study was carried out. SETTING University hospital. PATIENTS Surgical patients with severe comorbidities. INTERVENTION The outcomes of 1218 surgical patients treated in intensive care units (ICUs) and postsurgical wards (ICU group vs. non-ICU group) were reviewed for poor outcomes (i.e., no discharge or death). A propensity score analysis was used to generate 248 matched pairs of ICU-admitted patients and controls. VARIABLES OF INTEREST Poor outcome rates on postoperative day 90 and mortality on postoperative days 30 and 90. RESULTS No significant between-group differences were observed in terms of poor outcomes on postoperative day 90 [ICU vs. non-ICU: 33/248 (13%) vs. 28/248 (11%), respectively; ICU odds ratio (OR): 1.19, 95% confidence interval (CI), 0.71-2.01, p=0.596] or in between-group differences in terms of mortality on postoperative days 30 and 90 [ICU vs. non-ICU: 4/248 (1.6%) vs. 2/248 (0.8%) on postoperative day 30 and 5/248 (2.0%) vs. 3/248 (1.2%) on day 90, respectively; ICU OR (95% CI), 2.00 (0.37-10.9) and 1.67 (0.40-6.97) for postoperative 30- and 90-day mortality, respectively (p=0.683 and 0.724)]. Low preoperative body weight was negatively correlated to patient outcomes [OR (95% CI): 0.82/10kg (0.70-0.97), p=0.019], whereas regional analgesia combined with general anesthesia was positively correlated to patient outcomes [OR (95% CI): 0.39 (0.69-0.96), p=0.006]. Extra ICU admission was correlated to poor patient outcomes [OR (95% CI): 4.18 (2.23-7.81), p < 0.0001]. CONCLUSIONS Postoperative ICU admission failed to demonstrate any meaningful benefits in patients with severe comorbidities undergoing miscellaneous elective surgeries.
Collapse
Affiliation(s)
- T Ogawa
- Division of Intensive Care, Nara Medical University, 840 Shijo-cho Kashihara, Nara 634-8521, Japan
| | - S Inoue
- Division of Intensive Care, Nara Medical University, 840 Shijo-cho Kashihara, Nara 634-8521, Japan.
| | - M Inada
- Division of Intensive Care, Nara Medical University, 840 Shijo-cho Kashihara, Nara 634-8521, Japan
| | - M Kawaguchi
- Division of Intensive Care, Nara Medical University, 840 Shijo-cho Kashihara, Nara 634-8521, Japan
| |
Collapse
|
39
|
Nagano M, Saito K, Kozuka Y, Shibusawa M, Imai N, Noro A, Kageyama Y, Mizuno T, Ogawa T, Katayama N. PD-L1 expression on circulating monocytes in patients with breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy427.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Hanai N, Asakage T, Kiyota N, Homma A, Monden N, Fukushima H, Fujii T, Ogawa T, Tanaka K, Mizusawa J, Eba J, Hayashi R. A randomized phase III study to evaluate the value of the omission of prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
41
|
Enokida T, Ogawa T, Homma A, Okami K, Minami S, Iwae S, Nakanome A, Shimizu Y, Motegi A, Maki D, Ueda Y, Fujisawa T, Nomura S, Okano S, Tahara M. A multicenter phase II trial of paclitaxel, carboplatin and cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Ogawa Y, Naganuma A, Inagawa M, Iida T, Kimura M, Kumakura A, Yoshida T, Yamai N, Moroboshi A, Ueda R, Kawahara Y, Itou N, Shiozawa Y, Koyama Y, Funakoshi H, Manome M, Noguchi K, Kanai M, Ishiguro K, Ogawa T, Ishihara H. Effect of video endoscopic examination of swallowing function early after admission on length of hospital stay for patients with acute cerebral infarction: A retrospective study. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.1150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
43
|
Uehara D, Naganuma A, Hoshino T, Horiguchi S, Murakami T, Kudo T, Ishihara H, Ogawa Y, Inagawa M, Tanaka T, Ogawa T, Sohara N, Hatanaka T, Sato K, Kakizaki S. Evaluation of liver fibrosis using bioelectrical impedance analysis and serum lipid profiles in patients with hepatitis c treated with direct acting antivirals. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.1433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Kang R, Nagoshi T, Kimura H, Tanaka T, Yoshii A, Ogawa K, Minai K, Ogawa T, Kawai M, Yoshimura M. P883Thermogenic action of B-type natriuretic peptide in patients with cardiovascular diseases according to covariance structure analysis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- R Kang
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - T Nagoshi
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - H Kimura
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - T Tanaka
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - A Yoshii
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - K Ogawa
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - K Minai
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - T Ogawa
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - M Kawai
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| | - M Yoshimura
- Jikei University School of Medicine (Tokyo), Division of Cardiology, Department of Internal Medicine, Tokyo, Japan
| |
Collapse
|
45
|
Nanto M, Goto Y, Yamamoto H, Tanigawa S, Takado M, Ogawa T, Nakahara Y. Periprocedural Outcomes of Carotid Artery Stenting in Elderly Patients. J Vasc Surg 2018. [DOI: 10.1016/j.jvs.2018.05.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Koizumi H, Ogawa T. Rapid and Sensitive Method to Measure Premature Yeast Flocculation Activity in Malt. Journal of the American Society of Brewing Chemists 2018. [DOI: 10.1094/asbcj-63-0147] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- H. Koizumi
- Central Laboratories for Frontier Technology, Kirin Brewery Co., Ltd. 1-13-5, Fukuura Kanazawa-ku Yokohama-shi Kanagawa 236-0004, Japan
| | - T. Ogawa
- Central Laboratories for Frontier Technology, Kirin Brewery Co., Ltd. 1-13-5, Fukuura Kanazawa-ku Yokohama-shi Kanagawa 236-0004, Japan
| |
Collapse
|
47
|
Koizumi H, Kato Y, Ogawa T. Structural Features of Barley Malt Polysaccharides Inducing Premature Yeast Flocculation. Journal of the American Society of Brewing Chemists 2018. [DOI: 10.1094/asbcj-2009-0422-01] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- H. Koizumi
- Central Laboratories for Frontier Technology, Kirin Holdings Co., Ltd., Yokohama-shi, Japan
| | - Y. Kato
- Laboratory of Food Science, Faculty of Education, Hirosaki University, Hirosaki, Japan
| | - T. Ogawa
- Central Laboratories for Frontier Technology, Kirin Holdings Co., Ltd., Yokohama-shi, Japan
| |
Collapse
|
48
|
Koizumi H, Kato Y, Ogawa T. Barley Malt Polysaccharides Inducing Premature Yeast Flocculation and Their Possible Mechanism. Journal of the American Society of Brewing Chemists 2018. [DOI: 10.1094/asbcj-2008-0614-01] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- H. Koizumi
- Central Laboratories for Frontier Technology, Kirin Holdings Co., Ltd., Yokohama-shi, Japan
| | - Y. Kato
- Laboratory of Food Science, Faculty of Education, Hirosaki University, Hirosaki, Japan
| | - T. Ogawa
- Central Laboratories for Frontier Technology, Kirin Holdings Co., Ltd., Yokohama-shi, Japan
| |
Collapse
|
49
|
Ogawa T, Ishitsuka Y, Iwamoto K, Koguchi-Yoshioka H, Tanaka R, Watanabe R, Fujisawa Y, Fujimoto M. Programmed cell death 1 blockade-induced cutaneous sarcoid-like epithelioid granulomas in advanced melanoma: a case report. J Eur Acad Dermatol Venereol 2018; 32:e260-e261. [PMID: 29314333 DOI: 10.1111/jdv.14781] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- T Ogawa
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| | - Y Ishitsuka
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| | - K Iwamoto
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| | - H Koguchi-Yoshioka
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| | - R Tanaka
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| | - R Watanabe
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| | - Y Fujisawa
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| | - M Fujimoto
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture, Japan
| |
Collapse
|
50
|
Ogawa T, Kimoto S, Nakashima Y, Furuse N, Ono M, Furokawa S, Okubo M, Yamaguchi H, Kawai Y. Differences in pain thresholds elicited by intraoral electrical stimuli between individuals with and without diabetes mellitus. J Oral Rehabil 2018; 45:235-239. [DOI: 10.1111/joor.12601] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2017] [Indexed: 11/30/2022]
Affiliation(s)
- T. Ogawa
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - S. Kimoto
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - Y. Nakashima
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - N. Furuse
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - M. Ono
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - S. Furokawa
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - M. Okubo
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - H. Yamaguchi
- Department of Anesthesiology; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - Y. Kawai
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| |
Collapse
|